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Abstract  
Review of the current literature reveals inconsistent findings on potential 
associations between antidepressant use during pregnancy and adverse fetal and child 
health and development. This study aims to examine the effect of antenatal SSRI 
exposure on several neonatal (preterm birth, small- and large-for-gestational age, Apgar 
score, and neonatal intensive care unit admission) and child developmental outcomes 
(measured by Ages and Stages Questionnaire) while controlling for confounding by 
indication. Data were obtained from the Prenatal Health Project, a longitudinal cohort 
study of 2,357 women in London, Ontario. Results from univariable analysis discovered 
that infants exposed to in utero SSRIs were more likely to be large-for-gestational age 
compared to infants of women exposed to antenatal depressive symptoms but not SSRIs 
and to infants of women unexposed to either antenatal depression or SSRIs. The small 
sample size of the antidepressant-exposed population limited our study and further 
research is warranted to verify the significance of our findings.  
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: antenatal depression; antidepressants; selective serotonin reuptake inhibitors; 
SSRIs; pregnancy; neonatal outcomes; child developmental outcomes 
 
 
ii 
 
Acknowledgments  
First, I would like to express my sincere gratitude to my supervisor, Dr. Karen 
Campbell, for her ongoing support, encouragement, guidance, and patience throughout 
my time in the program. I would also like to extend my gratitude for Dr. Kathy Speechley 
in her role as a member of the advisory committee and more importantly, her role as the 
graduate chair. As well, I’m grateful to Dr. Verinder Sharma for providing input and 
expertise on the thesis. The support, words of encouragement, and advice from every 
member of the committee were integral towards the completion of the thesis project.  
Next, I would like to thank my family and friends who provided strong moral 
support throughout the process of graduate school. Especially my siblings, Jean and Jay, 
and my brother-in-law, Chris, whom all helped proofread this thesis. Also, I would like to 
dedicate a special thanks to my beloved dogs, Maya and Anca for always being there by 
my side. Lastly, my parents deserve all the thanks in the world for their unconditional 
love and encouragement every step of my academic journey.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
Table of Contents 
Abstract ................................................................................................................................ i 
Acknowledgments............................................................................................................... ii 
List of Tables ...................................................................................................................... v 
List of Figures ................................................................................................................... vii 
List of Appendices ........................................................................................................... viii 
List of Abbreviations ......................................................................................................... ix 
Chapter 1: Introduction, Rationale, and Objectives ............................................................ 1 
1.1 Research Objectives .................................................................................................. 2 
Chapter 2: Literature Review .............................................................................................. 3 
2.1 Overview ................................................................................................................... 3 
2.2 Depression during Pregnancy: Characteristics and Consequences ........................... 3 
2.2.1 Depression during Pregnancy: Prevalence......................................................... 3 
2.2.2 Symptoms and Consequences of Antenatal Depression .................................... 3 
2.2.3 Antenatal Depression Screening Tools .............................................................. 4 
2.2.4 Antenatal Depression Risk Factors .................................................................... 5 
2.2.5 Antenatal Depression: Adverse Neonatal Outcomes ......................................... 5 
2.2.6 Antenatal Depression: Child Developmental Outcomes ................................... 7 
2.3 Use of Selective Serotonin Reuptake Inhibitors (SSRIs) during Pregnancy: 
Characteristics and Consequences .................................................................................. 8 
2.3.1 Treatments of Antenatal Depression .................................................................. 8 
2.3.2 SSRIs.................................................................................................................. 8 
2.3.3 Characteristics of SSRI Use during Pregnancy ............................................... 10 
2.3.4 Adverse Neonatal Outcomes of SSRI Use during Pregnancy ......................... 11 
2.3.4.1 Neonatal Abstinence Syndrome (NAS) .................................................... 11 
2.3.4.2 Persistent Pulmonary Hypertension (PPHN) ............................................ 12 
2.3.4.3 Preterm Birth ............................................................................................. 13 
2.3.4.4 Apgar Score .............................................................................................. 14 
2.3.4.5 Neonatal Intensive Care Unit (NICU) ...................................................... 15 
2.3.4.6 Small-for-Gestational Age (SGA) ............................................................ 15 
2.3.4.7 Large-for-Gestational Age (LGA) ............................................................ 16 
2.3.5 Child Developmental Outcomes of SSRI Use during Pregnancy .................... 17 
2.3.5.1 Role of Serotonin ...................................................................................... 18 
2.3.5.2 Cognition/Problem Solving ...................................................................... 18 
2.3.5.3 Fine and Gross Motor Movements ........................................................... 19 
2.3.5.4 Communication/ Language Development ................................................ 20 
2.3.5.5 Personal/Social Behavioural Development............................................... 20 
2.3.5.6 Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity 
Disorder (ADHD) ................................................................................................. 21 
2.3.5.7 Covariates ................................................................................................. 22 
2.3.5.8 Summary of Long-Term Developmental Studies ..................................... 22 
 
 
iv 
 
Chapter 3: Methods ........................................................................................................... 24 
3.1 Secondary Data Source: The Prenatal Health Project............................................. 24 
3.1.1 Prenatal Phase .................................................................................................. 24 
3.1.2 Perinatal Phase ................................................................................................. 24 
3.1.3 Toddler/Childhood Phase................................................................................. 25 
3.2 Prenatal Health Project Cohort ............................................................................... 25 
3.3 Study Groups .......................................................................................................... 26 
3.4 Variables of Interest ................................................................................................ 27 
3.4.1 Baseline Maternal Variables ................................................................................ 27 
3.4.2 Prenatal Maternal Variables ................................................................................. 29 
3.4.4 Neonatal Outcome Variables ............................................................................... 30 
3.4.5 Developmental Outcome Variables ..................................................................... 31 
3.6 Statistical Analysis .................................................................................................. 32 
3.6.1 Preliminary Inspection and Handling of Dataset ............................................. 32 
3.6.2 Descriptive Analysis: Objective 1 ................................................................... 32 
3.6.3 Descriptive Analysis: Objective 2 ................................................................... 33 
3.6.4 Descriptive Analyses: Objective 3 ................................................................... 34 
3.6.5 Secondary Analyses ......................................................................................... 34 
Chapter 4: Results ............................................................................................................. 43 
4.1 Study Sample .......................................................................................................... 43 
4.2. Antidepressant Use ................................................................................................ 43 
4.3 Characteristics of the Study Groups ....................................................................... 44 
4.4 Study Groups and Outcomes .................................................................................. 46 
4.4.1 Neonatal Outcomes .......................................................................................... 46 
4.4.2 Developmental Outcomes ................................................................................ 47 
4.5 Secondary Analysis on the Reference Group ......................................................... 47 
4.6 Summary of Findings .............................................................................................. 49 
Chapter 5: Discussion ....................................................................................................... 64 
5.1 Discussion Pertaining to Objective 1: Study Group Baseline Characteristics ........ 64 
5.2 Discussion Pertaining to Objective 2: Neonatal Outcomes .................................... 67 
5.3 Discussion Pertaining to Objective 3: Toddler/Child Development....................... 70 
5.4 Strengths and Limitations ....................................................................................... 73 
5.5 Conclusion and Future Directions .......................................................................... 75 
References ......................................................................................................................... 78 
Appendices ........................................................................................................................ 89 
Curriculum Vitae .............................................................................................................. 96 
 
 
v 
 
 
List of Tables 
Table 3.1. Variable definitions of maternal characteristics ...............................................37 
Table 3.2. Variable definitions of neonatal outcomes .......................................................41 
Table 4.1. Antenatal antidepressant use. ...........................................................................51 
Table 4.2. Amount and frequency of antenatal antidepressant use ...................................52 
 
Table 4.3 Maternal characteristics in the four study groups: exposed to any 
antidepressant, exposed to SSRIs, exposed to maternal depressive symptoms without 
antidepressant use, and unexposed to either depressive symptoms or antidepressants .....53 
 
Table 4.4a Neonatal outcomes in the four study groups: exposed to any antidepressant, 
exposed to SSRIs, exposed to maternal depressive symptoms without antidepressant  
use, and unexposed to either depressive symptoms or antidepressants .............................55 
 
Table 4.4b The expected count in each study group (reference = unexposed to either 
depressive symptoms or antidepressants), the ratio of observed/expected, and the 95% 
Poisson confidence interval of the rate ratio of observed/expected ...................................55 
 
Table 4.4c The expected count in each study group (reference = exposed to depressive 
symptoms and unexposed to antidepressants), the ratio of observed/expected, and the  
95% Poisson confidence interval of rate ratio of observed/expected ................................56 
 
Table 4.5a Neonatal outcomes of term infants in the four study groups: exposed to any 
antidepressant, exposed to SSRIs, exposed to maternal depressive symptoms without 
antidepressant use, and unexposed to either depressive symptoms or antidepressants .....57 
 
Table 4.5b The expected count in each exposure group (reference = exposed to 
depressive symptoms and unexposed to antidepressants), the ratio of  
observed/expected, and the 95% Poisson confidence interval of rate ratio of 
observed/expected ..............................................................................................................58 
 
Table 4.6 Mean and the 95% Bootstrap Bias Corrected and accelerated (BCa)  
confidence interval of ASQ Scores from five domains of term toddlers in the four  
study groups: exposed to any antidepressant, exposed to SSRIs, exposed to maternal 
depressive symptoms without antidepressant use, and unexposed to either depressive 
symptoms or antidepressants .............................................................................................59 
 
Table 4.7 LGA frequency by maternal characteristics ......................................................60 
 
 
vi 
 
 
Table 4.8 Univariable and multivariable logistic regression of maternal characteristics 
and LGA.............................................................................................................................62 
 
 
 
 
 
vii 
 
List of Figures  
Figure 3.1. Prenatal Health Project recruitment flow chart ..............................................36 
 
Figure 4.1. Sample flow for the prenatal, perinatal, and postnatal phases: the flow 
pertains to the analyses for this thesis project ....................................................................50 
 
Figure B1: Conceptual model based on literature review: neonatal and developmental 
outcomes of antenatal depressive symptoms and antidepressant exposure .......................92 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
viii 
 
List of Appendices  
Appendix A: Animal model literature review on developmental outcomes ....................89 
 
Appendix B: Conceptual model ........................................................................................92 
 
Appendix C: Relevant sections from the Prenatal Health Project questionnaire .............93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ix 
 
List of Abbreviations 
 
SSRIs              Selective Serotonin Reuptake Inhibitors 
 
SNRIs              Serotonin-Norepinephrine Reuptake Inhibitors 
 
TCAs             Tricyclic Antidepressants 
 
MDD          Major Depressive Disorder 
 
CES-D                    Center for Epidemiologic Studies Depression Scale 
 
PHP                  Prenatal Health Project 
 
HPA-axis                Hypothalamic-Pituitary Adrenal Axis 
 
SGA             Small-for-Gestational Age 
 
IUGR                   Intrauterine Growth Restriction  
 
LGA              Large-for-Gestational Age 
 
NICU                                Neonatal Intensive Care Unit  
 
TSC                           Transferred to Specialized Care 
 
ASQ                            Ages and Stages Questionnaire 
 
OR                          Odds Ratio 
  
MR                    Morbidity Ratio  
 
BCa                   Bias Corrected and accelerated 
 
CI                                                                                                            Confidence Interval
1 
 
 
 
Chapter 1: Introduction, Rationale, and Objectives 
The decision to take medication during pregnancy is a challenge faced by many 
pregnant women as all medications may potentially carry a risk of harming the 
developing fetus. This is certainly the case for depressed women determining whether or 
not to take antidepressant treatment during pregnancy. In order to assist women with 
evidence-based decisions, researchers and clinicians are faced with different challenges 
of assessing the risks and benefits of antidepressant treatment against the risks of 
untreated depression on the developing fetus. Even with the considerable amount of 
research, however, the risk of antidepressant treatment during pregnancy on the fetus and 
child development has been unclear [1, 2].  
Due to ethical limitations in conducting randomized controlled trials (RCTs), all 
human studies to date that examined the safety and efficacy of antidepressant medication 
use during pregnancy on the subsequent neonatal and child development outcomes have 
been observational [3]. There are many challenges and limitations in designing an 
observational pharmacoepidemiological study in this field as well. The main challenge is 
in separating the effects of antidepressant use during pregnancy from the effects of 
underlying maternal antenatal depression on the outcomes of interest, since both have 
been individually found to be associated with adverse neonatal and long-term child 
developmental outcomes.  
 Therefore, the main goal for this thesis is to differentiate the effects between 
antenatal depression and in utero SSRI exposure on neonatal and child developmental 
outcomes. The majority of study designs in which outcomes of antidepressant exposure 
were investigated did not distinguish the effect of antenatal antidepressant use from any 
risk attached to the medical indications for antidepressant use, such as depression. Rather, 
studies have tended to compare an antidepressant exposure group to only the non-
exposed group, which results in confounding by indication.  
In this thesis, we will use a well-established prenatal cohort [4] in which data 
were collected prospectively. This allows us to design our study to reduce confounding 
by indication. In particular, we directly compare neonatal and child outcomes between 
those whose mothers had antenatal antidepressant use and antenatally depressed mothers 
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without antidepressant use, while using a group with neither exposure as the base 
comparison group. To our knowledge, only a small number of studies have this direct 
comparison for neonatal outcomes [5-8] and long-term developmental outcomes [9-13].  
It is anticipated that this study will contribute to our understanding of the risks 
versus benefits of antidepressant use during pregnancy, in comparison to untreated 
antenatal depression. As this literature evolves, it will assist health care professionals in 
making evidence-based decisions.  
 
1.1 Research Objectives 
The primary goal of this project is to examine the neonatal and long-term 
developmental outcomes of antidepressant use, with special interest in SSRI use during 
pregnancy in women from London, Ontario, by using secondary data source from 
Prenatal Health Project (PHP). The specific objectives of this thesis project are as 
follows: 
1. To describe the baseline characteristics of mothers who fit in the following study 
groups antenatally: 1) Antidepressant group: those who take antidepressants for 
any indication (indication unknown); 2) SSRI subgroup: those who take SSRIs; 3) 
Depressive Symptoms group: those who have elevated depressive symptoms but 
do not take antidepressants and; 4) Reference group: those who do not have 
elevated depressive symptoms and do not take antidepressants. 
2. To compare neonatal outcomes among the study groups. Specific neonatal 
outcomes of interest are: preterm delivery, small-for-gestational age (SGA), large- 
for-gestational age (LGA), Apgar scores at one (Apgar-1) and five (Apgar-5) 
minutes, and NICU admissions. 
3. To compare long-term development of toddlers and preschoolers (measured by 
Ages and Stages Questionnaire) among the study groups. 
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Chapter 2: Literature Review 
2.1 Overview 
 The structure of this chapter outlines the characteristics and consequences of 
antenatal depression and antidepressant use during pregnancy, as well as the individual 
effect of both on neonatal and child development outcomes. It should be noted that this 
literature review will mainly focus on selective serotonin reuptake inhibitors (SSRIs) as 
they are the most studied, prescribed, and used antidepressant in our focused population.    
 
2.2 Depression during Pregnancy: Characteristics and Consequences 
2.2.1 Depression during Pregnancy: Prevalence  
  Pregnancy was generally believed to be protective against depressive disorders 
and thought to be associated with the state of emotional well-being [14]. However, 
evidence for this claim is sparse and many women have increased risk of developing 
and/or sustaining depressive disorders during pregnancy [14]. In fact, the first onset peak 
of depression for women is during the childbearing years [15]. According to the a meta-
analysis conducted by Agency for Healthcare Research and Quality (AHRQ) [16], the 
point prevalence for combined major and minor depression during pregnancy was 
estimated to be 8.5 to 11.0 percent (3.1 to 4.9 percent for major depression alone) while 
the period prevalence of depressive disorder estimated from conception to birth was 14 to 
23 percent. Bennett et al. [17] reported that the prevalence of depression increases from 
7.4% in the first trimester to 12.8% in the second and 12.0% in the third trimester. 
Additionally, depression is a highly recurrent disorder and the risk of depressive relapse 
during pregnancy for women with a history of depression is approximately 43% [14]. 
Therefore depression is a prevalent condition affecting many women during pregnancy, 
notably more prevalent in disadvantaged groups such as young, single women with 
limited socioeconomical support [18].  
 
2.2.2 Symptoms and Consequences of Antenatal Depression 
Many pregnant women suffering from depression are often not recognized, or 
diagnosed, and subsequently not treated due to the similar features of depression and 
normal physiological and hormonal changes that occur during pregnancy such as changes 
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in mood, appetite, and sleep pattern [19]. The symptoms of antenatal depression are 
persistent low mood, loss of interest in daily activities, dramatic change in appetite, 
emotional disconnects with the unborn, negative thoughts, lack of self-care, and serious 
thoughts of suicide in severe cases [20, 21]. The consequences of these symptoms may 
lead to non-adherence to antenatal care, tobacco, alcohol, and drug use, poor weight gain 
or loss, poor nutrition, anxiety (strongly comorbid with depression), psychotic symptoms, 
preeclampsia, and post-partum depression [21, 22]. Despite the consequences and high 
prevalence of antenatal depression, many depressed pregnant women are under-treated or 
not treated at all [18, 23]. In a national survey, Dietrich et al. [24] found that fewer than 
half of obstetricians stated that residence training equipped them with the knowledge and 
training to recognize and treat depression. Additionally, the risk factors are not readily 
recognized [24]. 
 
2.2.3 Antenatal Depression Screening Tools 
Early detection of antenatal depression improves the chances of effective 
treatment of depression and may prevent major depressive disorder (MDD) [25]. 
Therefore, the American College of Obstetricians and Gynecologists (ACOG) endorses 
screening for depressive symptoms at least once during pregnancy using a validated tool 
[26]. One of the most widely used and validated depression screening tools in antenatal 
research is the Center for Epidemiologic Studies Depression Scale (CES-D) [25, 27]. As 
well, it is recommended as part of the initial assessment for antenatal depression [25]. 
The CES-D measures the depressive symptoms (cognitive, somatic, affective, and 
behavioural) experienced by the participant in the past week [27]. The scale has 20 items 
and the score ranges from 0 to 60. A cut-off point of ≥16 is typically used to indicate 
clinical depression with a sensitivity and specificity of 60% and 92%, respectively [27].  
Other tools such as the Edinburgh Postnatal Depression Scale (EPDS), Beck 
Depression Inventory (BDI), the BDI-II, the Patient Health Questionnaire-2 (PHQ-2), 
and the Pregnancy Depression Scale (PDS) are also implemented in antenatal health 
studies [25]. It is important to note that these tools do not serve as diagnostic tests for 
depression but rather indicate depressive symptoms and the possible risks of developing 
depressive disorder. To be clinically diagnosed with MDD by a physician, the patient 
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must fit the diagnostic criteria as described in the Diagnostic and Statistical Manual of 
Mental Disorders 5th edition (DSM-5), which includes depressed mood or loss of pleasure 
in all or most of one’s usual activities for more than 2 weeks and have experienced at 
least 5 out of 9 specific clinical features (depressed mood, significant weight change, 
insomnia or hypersomnia, suicidality, etc.) for nearly every day [28].  
 
2.2.4 Antenatal Depression Risk Factors  
Antenatal depression is associated with many factors including sociodemographic 
status, psychiatric comorbidities, life stresses, relationship quality, social support, 
substance abuse, and obstetric history [29]. A systematic review performed by Lancaster 
et al. [29] set out to identify the risk factors for antenatal depression that can be assessed 
in routine obstetric care. From 57 studies, they found that life stress, lack of social 
support, and domestic violence to be the strongest correlates with antenatal depression in 
their multivariable analyses. On the other hand, maternal anxiety, history of depression, 
unintended pregnancy, lower income, lower education, smoking, single status, and poor 
relationship quality were strongly associated with antenatal depression in their bi-variable 
analyses. Pregnant women with these risk factors are considered at high risk of 
developing antenatal depression and should be screened for depressive symptoms.  
 
2.2.5 Antenatal Depression: Adverse Neonatal Outcomes  
Depression during pregnancy has negative health consequences for both the 
mother and child. Antenatal depression has been found to be associated with increased 
risk of adverse neonatal events such as preterm delivery [30, 31], low birth weight [30, 
31], intrauterine growth restriction (IUGR) [32, 33], and admissions to Neonatal 
Intensive Care Unit (NICU) [33]. The postulated mechanism is the dysregulation of the 
hypothalamic-pituitary adrenal axis (HPA-axis), sympathetic nervous system, and 
inflammatory system [34]. The increased secretion of maternal stress hormones such as 
corticotrophin releasing hormone, cortisol, and catecholoamines may directly or 
indirectly impact fetal development and epigenetically program the HPA-axis of the fetus 
via DNA methylation, which could potentially have long-term developmental 
consequences as well [35, 36]. In addition to the biological mechanisms, pregnant women 
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with depressive symptoms are also less likely to take care of themselves or to attend to 
antenatal care, and more likely engage in unhealthy lifestyle behaviours such as smoking 
and alcohol consumption that exacerbate the risk of adverse pregnancy outcomes [1, 35].  
Numerous studies have examined the relationship between antenatal depression 
and adverse neonatal outcomes; however, many of these studies have methodological 
limitations due to lack of proper controls for confounders and size sample issues. In 
addition, the heterogeneity of study design further complicates the comparability of 
results [35]. The confounders that are inadequately controlled in most studies are the 
severity of depression, demographic factors, substance abuse, and comorbid psychosocial 
factors such as anxiety and self-reported stress [30, 35, 37]. Therefore, the findings for 
adverse neonatal outcomes such as preterm delivery, low birth weight, small-for-
gestational age (SGA), low Apgar score, and admission to NICU are inconsistent.  
Szegda et al. [35] critically reviewed studies that investigated antenatal 
depression and adverse neonatal outcomes including preterm birth, low birth weight, and 
SGA. Out of 27 studies, 12 found that antenatal depression, particularly early to mid-
pregnancy, increased the risk of preterm birth with an odds ratio (OR) range of 1.3 to 4.9. 
The association between antenatal depression and low birth weight was less consistent as 
only 6 out of 20 studies discovered an increased risk with OR range of 1.4 to 2.2. An 
increased risk of SGA in infants exposed to antenatal depression, particularly during 
early to mid-pregnancy, was found in 5 out of 10 studies. A meta-analysis conducted by 
Grote et al. [30] gathered 29 prospective observational studies (n=48,004) and calculated 
the pooled relative risk. They found that antenatal depression was significantly associated 
with preterm birth (pooled RR: 1.13; 95% Confidence Interval (Cl): 1.06-1.21) and low 
birth weight (pooled RR: 1.18; 95% Cl: 1.07-1.30). Antenatal depression was not 
significantly associated with IUGR since only 2 out of 12 studies found this association. 
Conversely, another meta-analysis performed by Grigoriadis et al. [37] assessed the 
association between antenatal depression and adverse neonatal outcomes including 
premature delivery, gestational age, birth weight, NICU admission, and Apgar scores at 1 
and 5 minutes. They examined 30 prospective observational studies and found an 
increased risk of premature delivery (OR: 1.37; 95% CI: 1.04-1.81) for depressed 
mothers during pregnancy. Other adverse neonatal outcomes were not found to be 
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significant. The postulated reasons for these discrepancies in results include the 
heterogeneity of study design, specifically the different tools used to measure depression, 
difference in the timing and severity of exposure, different confounding variables 
controlled, and different sample populations and sizes. 
 
2.2.6 Antenatal Depression: Child Developmental Outcomes 
Antenatal depression has been found to be associated with poorer child 
development including higher risk of cognitive delay [38-41], behavioural/social 
problems [38, 42, 43], reduced emotional ability [41], and attention problems [44] even 
after considering the confounding effects of other antenatal and postnatal risk factors. For 
instance, a prospective cohort study (n=10,125) examined the association between 
maternal depressive symptoms during pregnancy and child development at 18 months of 
age found that persistent depression (EPDS ≥ 10 at 18 and 32 weeks of gestation) was 
associated with developmental delay (OR: 1.34; 95% Cl: 1.11-16.2) for 18 month olds 
when adjusted for smoking, maternal age, and life events [38]. The association remained 
significant after adjustment for postnatal depression, although the effect was slightly 
attenuated.  
Furthermore, the effects of antenatal depression have been illustrated be a 
predictor of violence [42] and depression [45] in adolescents. Pawlby et al. [45] 
conducted a prospective longitudinal community-based study and followed 84% (n=127) 
of the mother-child dyads from pregnancy to 16 years later. Psychological problems were 
assessed for adolescents at 16-years-old using the Child and Adolescent Psychiatric 
Assessment, in which 14% (18/127) were diagnosed with depressive disorder. The 
adolescents exposed to antenatal depression (11/17) had a 4.7 times greater odds (95% 
Cl: 1.60-13.86) of suffering from depression compared to youths not exposed. However, 
this effect was mediated by cumulative exposure to maternal depression during the 
lifetime of the child.  
To add to this, antenatal depression is a strong predictor of postpartum depression 
[21]. It is well-documented in the literature that postpartum depression has a negative 
effect on mother-infant bonding and subsequent child development [46]. Hence, there are 
difficulties in examining the individual effect of antenatal depression on long-term child 
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development and adjusting for postnatal depression given that postnatal depression may 
be an intermediate in the causal pathway or a standalone factor influencing child 
development [38]. With that said, the effect of antenatal depression on child development 
is substantial and estimated to explain 10-15% of the poor emotional and behavioural 
outcomes in children [47].  
 
2.3 Use of Selective Serotonin Reuptake Inhibitors (SSRIs) during Pregnancy: 
Characteristics and Consequences 
2.3.1 Treatments of Antenatal Depression  
  Given the potential negative consequences of antenatal depression on the well-
being of the mother-child dyad, it is important that women with depressive symptoms 
during pregnancy seek treatment. Antenatal depression can be treated or managed with 
two main modalities: depression-specific psychotherapy and pharmacotherapy. For 
pregnant women who are not suicidal and drug naïve (new to treatment for the illness) 
with mild to moderate symptoms of depression, interpersonal psychotherapy is 
recommended as initial treatment [48, 49]. For pregnant women who are suicidal or with 
moderate to severe depression and have past history of good response to medication, 
pharmacotherapy is recommended, specifically SSRIs, as the first line treatment, and is 
often supplemented with psychotherapy [49]. 
 Other classes of antidepressant prescribed during pregnancy are: serotonin-
norepinephrine reuptake inhibitors (SNRIs), norepinephrine-dopamine reuptake 
inhibitors (NDRIs), serotonin antagonist and reuptake inhibitors (SARIs), and tricyclic 
antidepressants (TCAs). In a large Québec study of 97,680 database subjects, Ramos et 
al. [50] found that SSRIs (64.4%), SNRIs (12.3%), and TCAs (12.1%) were the three 
most commonly used classes of antidepressants during pregnancy.  
 
2.3.2 SSRIs 
Currently the most prescribed class of antidepressants during pregnancy is SSRIs, 
second-generation antidepressants [48, 50]. Although the first-generation antidepressants 
such as TCAs are as effective in managing depressive symptoms as SSRIs, first-
generation antidepressants have a high adverse effect profile and narrower therapeutic-
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toxicity window with common side effects of hypotension, sedation, and other 
anticholinergic effects [51]. Additionally, unlike TCAs, SSRI overdose does not cause 
cardiotoxicity and overdose-related death is rare [51]. However, there remain side effects 
that accompany SSRI use, such are nausea, headache, sexual dysfunction, weight gain, 
serotonin syndrome (headache, sweating, tremor), and increased risk of suicide in some 
(within the first to second month of treatment, especially noted in youth and young 
adults) [52]. There are currently six SSRIs available on the market in Canada: citalopram 
(Celexa), escitalopram (Lexapro), fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine 
(Paxil), and sertraline (Zoloft) [51], all of which are approved for MDD treatment, except 
for fluvoxamine, which is only approved for obsessive compulsive disorder [53]. 
Clinicians also prescribe SSRIs for other approved or unlabeled therapeutic uses other 
than MDD, including anxiety disorder, obsessive-compulsive disorder, panic disorder, 
social phobia, post-traumatic stress disorder, premenstrual dysphoric disorder, and eating 
disorder [54].  
Although as a class, various SSRIs share the basic mechanism of action, the 
chemical structures of different types of SSRIs are considerably distinct. Consequently, 
the pharmacokinetics properties, including absorption, distribution, metabolism, and 
elimination of the medications are quite dissimilar [55]. Hence, the dosages administrated 
and half-lives, which range from days to hours, are distinctive. For example, the half-life 
of norfluoxetine, active metabolite of fluoxetine, is 7 days, so patients who abruptly 
discontinue fluoxetine are less likely to suffer from discontinuation syndrome [55]. In 
addition, specific SSRIs are metabolized by different hepatic cytochrome P450 enzymes 
(CYPs) therefore blood concentration of metabolites highly depends on interindividual 
variability [55]. 
The main mechanism of action of SSRIs is via inhibition of the neuronal 5-
hydroxytryptamine (5-HT) reuptake pump at the serotonergic synapse without affecting 
other neuroreceptors [55, 56]. SSRIs decrease the efficiency of the serotonin reuptake 
pump by 60% to 80%, thereby increasing the concentration of serotonin (5-
hydroxtryptamine, 5-HT) at the synaptic gap, and further enhancing serotongeric 
neurotransmission [56]. Serotonin is known as the neurotransmitter associated with 
complex emotions, such as affection and happiness [57]. However, the serotonin-
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deficiency syndrome offers a simplistic explanation for the complex pathology of 
depression. The alternative theory explains the root cause of depression as due to the 
deficiency of synaptogenesis and neurogenesis. An indirect effect of SSRIs activate the 
signal transduction pathway on serotonergic neurons, which causes an increase 
expression of regulatory factors such as Brain Derived Neurotropic Factor (BDNF) [58]. 
The functions of BDNF are to promote 5-HT neuron and synapse growth, differentiation, 
and survival [58]. Overall, a concrete theory on the pathology of depression has yet to be 
settled and the exact mechanisms of action of SSRIs are still under investigation. 
 
2.3.3 Characteristics of SSRI Use during Pregnancy 
It is estimated that 7% to 13% of pregnant women in the United States (US) use 
SSRIs [59] and approximately 2.3% of 4 million infants born in the US each year are 
exposed to in utero SSRIs according to the data from National Birth Defects Prevention 
Registry [60]. Also, the rate of SSRIs use during pregnancy has increased over past 
decade in North America [61] For example, in British Columbia, Canada, SSRI use 
during pregnancy doubled from 2.3% to 5% between 1998 and 2001 [6].   
Ramos et al. [50] discovered that the prevalence rate of antidepressant use 
decreased significantly from 6.6% during the 12 months before the first day of gestation 
to 3.7% in the first trimester. This decreasing trend continues to the second (1.6%) and 
third trimester (1.1%) then significantly increases again to 7% during the 12 months after 
the end of pregnancy. Their results suggest that pregnant women are hesitant to continue 
treatment during pregnancy or healthcare providers are cautious about prescribing 
antidepressants during pregnancy. Pregnant women who discontinue antidepressant 
treatment are at an increased risk of relapse and withdrawal symptoms [14], which as 
aforementioned has negative consequences for the mother and fetus.  
Ramos et al. [50] also found several predictors of antidepressant use on the first 
day and the end of pregnancy, which were advanced maternal age, recipient of welfare, 
having a higher number of prescription medications, a higher number of prescribers, a 
higher number of visits to physicians before pregnancy, and a depression diagnosis 
before or during pregnancy. These predictors suggest that women who initiated or opted 
11 
 
 
 
to continue antidepressant treatment during pregnancy were likely to have more severe 
depressive symptoms compared to women who did not initiate or discontinued.  
According to the Food and Drug Administration (FDA), all SSRIs, except 
paroxetine, are classified as Pregnancy Category C drugs, meaning the risk is not ruled 
out given the lack of sufficient and well-controlled human studies to support animal 
studies that have produced evidences of adverse effect on the fetus [1, 61]. Paroxetine is 
labeled as Pregnancy Category D drug, which means there is positive evidence of fetal 
risk from human studies, specifically cardiovascular malformations [1, 61]. However, the 
potential benefits of both Categories C and D drugs may permit their use during 
pregnancy even with their potential risks [61].  
   
2.3.4 Adverse Neonatal Outcomes of SSRI Use during Pregnancy 
SSRIs are known to cross the human placenta so there are concerns over the 
impact of their use during pregnancy on fetal development and health [62]. In addition, 
the use of SSRIs during pregnancy remains controversial due to inconsistent results 
regarding the risks of their use on several adverse neonatal outcomes. For instance, SSRI 
usage late in pregnancy is known to be linked to a small increase in the risk of two 
adverse neonatal effects: neonatal abstinence syndrome (NAS) and persistent pulmonary 
hypertension (PPHN), although there are conflicting reports. Similarly, the finding for 
other adverse neonatal outcomes such as preterm birth, SGA, Apgar score at 1 and 5 
minutes, and NICU admission have been inconsistent in the literature.  
 
2.3.4.1 Neonatal Abstinence Syndrome (NAS) 
NAS or poor neonatal adaptation syndrome (PNAS) has been linked to exposure 
to SSRIs in the late third trimester and is characterized by a list of signs and behaviours 
that include irritability, abnormal crying, tremour, respiratory distress, digestive 
disturbance, hypoglycemia, hypothermia, hyperreflexia, sleep disturbance, feeding issues, 
and seizures [63]. These signs and behaviours are usually self-limiting and abate within a 
few days to 2 weeks with strategies such as decreasing sensory stimulus and ensuring 
skin-to-skin contact between mother and infant [64]. Neonates with severe NAS require 
further monitoring and nursing in the NICU [65]. The pathophysiology of NAS is thought 
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be caused by the serotonergic withdrawal effect or overstimulation of serotonergic 
system from in utero SSRI exposure [63].  
In a cohort study, Levinson-Castiel et al. [66] used the Finnegan score to assess 
NAS of 120 term infants. Of the 60 infants exposed to in utero SSRIs, 18 (30%) showed 
mild to severe symptoms of NAS whereas all non-exposed infants had normal Finnegan 
scores. In a review, Moses-Kolko et al. [64] calculated the risk ratio (RR) and 95% CI 
from the raw data of 5 cohort studies that examined the relationship between antenatal 
SSRI exposure and NAS and found that late SSRI exposure was associated with an 
increased risk (RR: 3.0; 95% CI: 2.0-4.4) of neonatal abstinence syndrome compared to 
early SSRI and no SSRI exposure. Consequently, these infants were admitted to special 
care nursery units (RR: 2.6; 95% CI: 1.4-4.7) and the hospital lengths of stay were 
longer. Furthermore, a meta-analysis [67] of 12 studies, which aggregated to 3780 infants 
exposed to antidepressants, found in utero antidepressants exposure was associated with 
NAS (OR: 5.07; 95% CI: 3.25-7.90), respiratory distress (OR: 2.20; 95% CI: 1.81-2.66), 
and tremours (OR: 7.89; 95% CI: 3.33-18.73)  
Therefore the literature on the effect of late SSRI exposure on NAS has been quite 
consistent. The FDA has issued a warning for physicians and mothers to be aware the risk 
of NAS if taking antidepressants late in pregnancy, especially paroxetine due to its short 
half-life [65]. 
 
2.3.4.2 Persistent Pulmonary Hypertension (PPHN) 
PPHN occurs when the pulmonary vascular resistance or blood pressure remains 
elevated after birth in newborns. This causes blood circulation to shunt from the right to 
the left side of the circulatory system (away from the lungs), resulting in hypoxemia [68]. 
PPHN is estimated to occur in 1 or 2 infants per 1000 live births and is associated with 
increased rate of mortality (10-20% even after treatment) and morbidity [68]. Due to 
compromised tissue oxygenation, survivors have increased risk of cognitive delay, 
hearing loss, and neurological abnormalities [69]. The findings on the relationship 
between SSRI exposure and PPHN have been inconsistent where some studies have 
found in utero SSRI exposure increases the risk of PPHN [68, 70-72], while others have 
not [73, 74].  
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A multinational population-based study [71] of over 1.6 million infants 
discovered that newborns whose mothers filled a prescription for SSRIs later than 20th 
week of gestation had a high risk of PPHN (adjusted OR: 2.1; 95% CI: 1.5-30). The 
absolute risk of PPHN was 2.9 per 1000 live births for SSRI-exposed infants versus 1.2 
per 1000 live births for infants not exposed. A recent meta-analysis [72] of seven high 
quality studies showed that late pregnancy exposure to SSRIs was associated with PPHN 
(OR: 2.50; 95% CI: 1.32-4.73), but not early pregnancy exposure to SSRIs. Clinically 
speaking, the absolute risk of PPHN after late pregnancy SSRI exposure remained small 
at 2.9 to 3.5 per 1000 live births since it is a rare disease. In 2011, the FDA revised their 
warning and recommended that physicians continue their standard practice, as the 
findings are still inconclusive [65].  
 
2.3.4.3 Preterm Birth  
Preterm birth is defined as the birth of the neonate at less than 37 weeks of 
pregnancy [7] and continues to be one of the leading causes of neonatal and infant 
mortality and morbidity in developed nations [75]. Approximately 75% of perinatal 
mortality occurs in premature infants [75]. Additionally, premature infants are at higher 
risk of having neonatal complications and chronic health problems [75].  
Findings on the relationship between in utero SSRI exposure and preterm birth 
have been inconsistent, as some studies have found evidence of a significant association 
between in utero SSRI exposure and preterm birth [5, 7, 8, 76-80] whereas others have 
not [63, 81, 82]. A retrospective cohort study of 33,791 mother-child pairs was conducted 
by Grzeskowiak et al. [7] to investigate the neonatal outcomes of infants exposed to in 
utero SSRIs during late gestation. They found that infants exposed to SSRIs during 
pregnancy had an increased risk of preterm delivery compared to infants whose mothers 
had psychiatric illness but no SSRI use (adjusted OR: 2.68; 95% CI: 1.83-3.93) and 
compared to infants whose mothers had no psychiatric illness at all (adjusted OR: 2.46; 
95% CI: 1.75-3.50). A meta-analysis of 14 studies documented that antidepressant use 
during pregnancy was significantly associated with an increased risk of preterm birth 
(pooled OR: 1.55; 95% CI: 1.38-1.74) [80]. However, the clinical significance is 
questionable given the gestational age of neonates exposed to in utero SSRIs was three 
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days shorter than non-exposed neonates. A comparison of depressed women who took 
antidepressants during pregnancy versus depressed women who did not take 
antidepressants during pregnancy in five studies showed a marginal trend toward 
significance (pooled OR: 1.58; 95% CI: 0.97-2.56) suggesting that the effect of 
antidepressant use on preterm birth is perhaps independent of maternal depression [80]  
Moreover, underlying maternal depression may be a significant confounding 
factor in the observed association between antenatal SSRI exposure and preterm birth. A 
prospective observational study (n=2,793) found an increased risk of preterm birth among 
women who took SSRIs during pregnancy with (OR: 2.1; 95% CI: 1-4.6) or without (OR: 
1.6; 95% CI: 1.0-2.5) a major depressive episode. However, untreated women with a 
major depressive episode did not have increased risk of preterm birth [83]. After 
controlling for illness severity factors (age of illness onset, number of hospitalizations, 
number of depressive episodes, and suicidal ideation.), the effect of antenatal SSRI 
exposure on preterm birth was attenuated and no longer significant.   
 
2.3.4.4 Apgar Score  
Apgar score is a method used to assess the health of the newborn immediately 
after birth to determine whether the newborn requires immediate medical care [84]. It is 
based on five criteria: appearance/complexion (cyanosis, acrocyanosis, or no cyanosis), 
pulse rate (absent, <100 beats/minute, or >100 beats/minute), reflex irritability grimace 
(no response to stimulus, grimace on stimulus, or cry on stimulus), activity (no flexion, 
some flexion, or arms and legs resistance), and respiratory effort (no cry, weak gasping, 
or strong cry). The overall score is out of 10 with each criterion scored from 0 to 2 [84]. 
A score of 7 or higher is considered normal and 3 and below is critically low. The 
assessment is usually administrated at one and five minutes after birth and repeated if the 
score remains low. A low score at the one-minute test may indicate the newborn needs 
further medical attention but typically the score improves with subsequent Apgar 
calculations. If the score persists to be severely low at 10, 15, or 30 minutes, it is taken as 
an indication that the newborn may suffer from neurological problems in the long run 
[84].  
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Many studies have documented the relationship between in utero SSRI exposure 
and low Apgar scores [8, 76, 78, 85]. In a prospective cohort study, Lund et al. [8] 
compared neonatal outcomes among 329 pregnant mothers exposed to SSRI treatment, 
4902 pregnant women who had a history of psychiatric illness but no SSRI exposure, and 
51,770 pregnant women with no psychiatric history. Infants exposed to in utero SSRIs 
had an increased risk of scoring 7 or below for the 5-minute Apgar compared to infants 
whose mothers had a history of psychiatric illness (adjusted OR: 6.58; 95% CI: 3.39-
12.74), and to infants whose mothers had no history of psychiatric illness (adjusted OR: 
6.58; 95% CI: 3.39-12.74).  
 
2.3.4.5 Neonatal Intensive Care Unit (NICU) 
Several studies have documented that newborns exposed to in utero SSRIs are at 
an increased risk of admission to NICU [6-8, 63]. A potential explanation is that neonates 
exposed to in utero SSRIs have higher risk of developing NAS. Lund et al. [8] reported a 
higher rate of NICU admission among newborns exposed to SSRIs in utero compared to 
newborns whose mothers did not have a history of psychiatric illness (adjusted OR: 2.39; 
95% CI: 1.69-3.39) and to newborns whose mothers did have a psychiatric history 
(adjusted OR: 2.04; 95% CI: 1.42-2.94). Comparable results with similar adjusted OR 
and 95% CI was reported by Grzeskowiak et al. [7]. Furthermore, a meta-analysis of 9 
studies designed to investigate the relationship between late pregnancy SSRI exposure 
and NAS reported that late pregnancy exposure to SSRIs is associated with an increased 
risk of NICU admissions (OR: 3.3; 95% CI: 1.45-7.54) [63]. In contrast, Suri et al. [86] 
did not find an increase in NICU admission in infants exposed to in utero SSRIs.  
 
2.3.4.6 Small-for-Gestational Age (SGA) 
SGA is defined as birth weight less than the 10th percentile for gestational age [7]. 
Of newborns who are defined as SGA, 70% are just constitutionally small and not at risk 
of neonatal complications [87]. SGA in newborns who are not constitutionally small are 
likely intrauterine growth restricted (IUGR) as a result of reduced oxygen and nutrient 
supply to the fetus due to genetic or environmental factors [7]. Consequently, the fetus is 
unable to reach its genetically programed potential growth. In addition, SGA in infants 
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with birth weight lower than the 3rd percentile for gestational age typically have severe 
IUGR, which can lead to neonatal complications including impaired thermoregulation, 
hypoglycemia, polycythemia, impaired immune system, and increased risk of mortality 
(4 to 8 times higher risk of mortality) [88]. Infants born SGA are also at increased risk of 
having health problems later in life such as psychiatric disorders [89], cardiovascular 
disease [90], and metabolic syndrome [90]. Thus far, the majority of studies have only 
examined birth weight without accounting for gestational age so infants categorized as 
low birth weight (<2500g) may include those of low gestation with appropriate birth 
weight for their gestational age. Risk factors associated with SGA and IUGR can be 
categorized into 3 classifications: maternal, fetal, and placental. Maternal factors include 
vasculopathy disorders (preeclampsia, nephropathy), virus infections, maternal substance 
abuse (smoking, alcohol use, illicit drug use), and other maternal demographic variables 
(race, age, and parity) [91]. Fetal factors involve genetic abnormalities and major 
congenital anomalies of the fetus. Lastly, placental factors include abnormal placental 
blood circulation and chronic placental inflammatory lesions [92]. 
Some studies have found an association between in utero SSRI exposure and 
SGA [6, 89] while others have not [7, 78, 85]. Oberlander et al. [6] used population 
health data to link records of neonatal birth outcomes with maternal health and antenatal 
SSRI prescription records and identified 1,451 depressed mothers treated with SSRIs, 
14,234 depressed mothers without treatment, and 92,192 controls. They discovered that 
birth weight and gestational age were significantly lower for neonates exposed to SSRIs 
compared to neonates exposed to antenatal depression, but birth weight at less than 10th 
percentile for gestational age was not significant. When propensity score matching was 
used to control for severity of maternal illness, SSRI-exposed infants had a significantly 
increased incidence of birth weight below the 10th percentile. 
 
2.3.4.7 Large-for-Gestational Age (LGA) 
LGA is defined as birth weight greater than 90th percentile for the gestational age 
[93]. From the US birth registry, infants born at 40 weeks gestational age at 90th 
percentile and 97th percentile have birth weight greater than 4000 grams and greater than 
4400 grams, respectively [94]. Infants weighing 4000 grams and beyond are diagnosed as 
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macrosomia and the morbidity, neonatal, and delivery (e.g. shoulder dystocia) 
complication rates increase at this threshold [93, 95]. Infants born LGA are also at risk 
for the development of Type II Diabetes Mellitus and metabolic syndrome later in life 
[95]. The incidence of macrosomia has increased in developed countries as maternal age, 
weight, and incidence of gestational diabetes at the time of pregnancy has increased and 
the prevalence of smoking decreased [95]. The maternal risk factors associated with 
excessive intrauterine growth are factors that cause excess delivery of nutrients to the 
fetus including maternal diabetes, maternal pre-pregnancy weight, and excess gestational 
weight gain [96]. Other risk factors are multiparity, advanced maternal age, post-term 
pregnancy, previous LGA birth, genetic syndromes, race and ethnicity [96].  
SSRI use has been found to be associated with weight gain (via stimulation of 
appetite) [97], insulin resistance [98], diabetes [99], and obesity [100] therefore SSRI use 
during pregnancy may indirectly influence LGA. Kallen et al. [78] used the Swedish 
Medical Birth Registry to identify and prospectively collect a sample of over half a 
million infants. Infants exposed to in utero SSRIs had an increased risk of being LGA 
compared to total population group after adjusting for confounders, but which did not 
reach statistical significance. The same result was found 6 years later in their follow-up 
study [85].  
 
2.3.5 Child Developmental Outcomes of SSRI Use during Pregnancy  
Studies on the long-term development of children exposed to in utero SSRIs are 
relatively limited compared to studies that examined adverse neonatal effects of SSRI 
exposure. Our literature review identified 26 observational studies that investigated the 
long-term child development outcomes of children born to mothers who took SSRIs 
during pregnancy: 14 prospective [9-11, 101-111], 6 retrospective [12, 13, 112-115], and 
6 case-control studies [116-121]. The age of the children involved in these studies ranges 
from infants (6-months-old) to adolescence (17-years-old in a case-control study on 
autism) with the majority of studies focused on children less than 6 years of age. 
Different studies implemented different developmental tests to measure a wide range of 
developmental outcomes. For example, for cognitive testing, the Bayley Scales of Infant 
Development, Wechsler Preschool and Primary Scale of Intelligence, or McCarthy Scales 
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were implemented by different studies. The sample size ranged from 22 children 
(prospective study) to 8,833 children (population-based register study) exposed to in 
utero SSRIs. The majority of the prospective studies had very small sample sizes. For 
instance, a sample cohort from British Columbia, Canada was followed longitudinally 
and examined in 3 different studies had an exposure group of ≤ 33 children [105-107]. 
The main developmental outcomes studied were organized into cognitive functioning, 
fine motor movement, gross motor movement, personal/social behavioural development, 
communication/language development, autism spectrum disorder (ASD), and attention 
deficit hyperactivity disorder (ADHD).  
 
2.3.5.1 Role of Serotonin 
As mentioned previously, SSRIs increase the serotonin availability in the neural 
network and are known to cross the placenta to the fetus [62]. In the early stages of 
embryogenesis, serotonin is one of the main signaling molecules vital for fetal 
neurodevelopment due to its importance in neuronal cell proliferation, migration, 
signaling, synaptogenesis, and ultimately development of the CNS [122]. Therefore, 
increased levels of serotonin during the crucial period of embryogenesis and fetal brain 
development may have adverse consequences. In animal models, the early administration 
of SSRIs in neonates and the subsequent increase in neural serotonin level have been 
found to influence fetal brain development, as seen in changes in neuronal structure of 
the somatosensory cortex and the related behavioural changes in adolescent rats [123] 
(See Appendix A for animal model literature review).  
Changes in serum protein levels integral for fetal neurodevelopment, such as 
Activing A and Reelin gene expression, have been found linked to in utero SSRI 
exposure in human studies [124, 125]. Additionally, serotonin is responsible for various 
physiological pathways and has an extensive role in the CNS involving cognition, 
memory, learning, and muscle tone [126].  
 
2.3.5.2 Cognition/Problem Solving 
No studies to date have found an association between in utero SSRI exposure and 
adverse cognitive outcomes [9, 101-104, 121] in children. A prospective study conducted 
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by Nulman et al. [9] recruited participants through the Motherisk Program and selected 
four different study groups: depressed women on Venlafaxine (SNRI) during pregnancy 
(n=62), depressed women on SSRIs during pregnancy (n=62), depressed women who 
were untreated (n=54), and healthy women (n=62). They reported that the children (3 to 
6-years-old) of healthy mothers had a significantly higher verbal and full scale IQ scores 
(measured by Wechsler Preschool and Primary Scale of Intelligence) than children whose 
mothers were on Venlafaxine and SSRIs while pregnant. However, by performing the 
regression analysis and accounting for confounders, maternal IQ was discovered to be a 
significant predictor for the child’s IQ. The difference found in verbal and full scale IQ 
between the children exposed to in utero SSRIs and children of healthy mothers was 
accounted for by maternal IQ and child’s gender and not by drug exposure. 
 
2.3.5.3 Fine and Gross Motor Movements 
Many studies have found an association between antenatal SSRI exposure and a 
deficiency in fine [103] and gross [12, 103, 104, 109] motor movement in children. 
Casper et al. [103] found that children (6 to 40-months-old) exposed to in utero SSRIs 
had significantly lower scores on the Bayley Psychomotor Developmental Index (scoring 
motor skills such as rolling, crawling, grasp, and use of utensils) and the Bayley 
Behavioural Rating Scales, specifically on fine motor movement and tremulousness sub-
scores. However, the study was underpowered with 31 children exposed to in utero 
SSRIs and 13 children in the control group. In a similar study [104], children with longer 
in utero exposure to SSRIs had an increased risk of having lower scores on the 
Psychomotor Developmental Index compared to controls. However, results from 
subsequent neurological examination discovered that the motor functioning of children 
remained within the normal range.  
A large population study [12] investigated the effect of antenatal SSRI exposure 
on normal milestone development at 6 and 19 months of age. Using the Danish National 
Birth Cohort database, a sample size of 81,946 was obtained and divided into 3 study 
groups: women on antidepressant during pregnancy (n=415), depressed women without 
antidepressant treatment (n=489), and non-depressed women (n=81,042). They found 
that at the sixth-month developmental milestone evaluation, children who were exposed 
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to SSRIs during the second and third trimesters had increased odds (adjusted OR: 2.1; 
95% CI: 1.23-3.60) of abnormal gross motor development, specifically sitting without 
support, compared to children of untreated mothers. However, this developmental delay 
was within normal range of development and resolved by 19 months of age.  
 
2.3.5.4 Communication/ Language Development 
A Norwegian population-based prospective pregnancy cohort study [111] of 
45,266 mothers with 51,748 children examined the language competency of 3-year-old 
children using the language grammar rating scale questionnaire. They reported that 
women with long-term SSRI use during pregnancy were more likely to have children 
with lower language competency compared to children whose mother did not take SSRIs 
during pregnancy. The underlying maternal anxiety and depression before and during 
pregnancy were independent of the observed moderate language delay. Whether the 
moderate language delay manifests later in the child’s life is unclear.  
Other than the above study by Skurtveit et al. [111], no other studies to date has 
found an association between in utero SSRI exposure and delayed 
communication/language development [101, 102, 109, 115].  
 
2.3.5.5 Personal/Social Behavioural Development 
Majority of studies did not indicate an association between antenatal SSRI 
exposure and personal/social behavioural problems in children [9, 10, 13, 101, 102, 106, 
107]; however, a few did [12, 104, 108, 110]. Casper et al. [104] found that longer 
antenatal exposure to SSRIs (throughout pregnancy) significantly increased the risk of 
lower Behavioural Rating Scale scores in 12-to-40-month-old children, particularly on 
orientation/engagement and emotional regulation (p=0.007). However, based on a 
subsequent neurological examination, mental development of children was found to be 
normal. Pedersen et al. [12] reported that children exposed to SSRIs in the second or 
third trimester had attention problems, specifically an inability to occupy themselves for 
15 minutes, at the 19th month milestone evaluation compared to children whose mother 
had untreated depression (OR: 2.1; 95% CI: 1.09-4.02) after adjusting for several 
covariates including postnatal depression. Another study longitudinally followed 30 
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children who developed SSRI-induced NAS and 52 children without NAS at the age of 2 
to 6 years [108]. They discovered that children with NAS had normal cognitive ability 
and developmental scores but were at an increased risk for abnormal social-behavioral 
development (OR: 3.03; 95% CI: 1.07-8.60) compared to 52 children without NAS [108]. 
In another small sample study, Hanley et al. [110] found that children exposed to in utero 
SSRIs had higher levels of internalizing behaviour (withdrawal, anxiety, depression) at 
three and six years of age compared to non-exposed children independent of maternal 
status of mood disorders throughout pregnancy and childhood.  
Misri et al. [107] and Oberlander et al. [106] assessed internalizing (emotional 
reactivity, withdrawal, irritability, depression, or anxiety) and externalizing (activity, 
attention, and impulsivity) behaviors, respectively, in four and five year olds who were 
and were not exposed to SSRIs antenatally. The level of internalizing behaviour was not 
different between the children in the exposed and non-exposed groups. Instead, maternal 
depression and anxiety were associated with an increase of internalizing behavior of their 
children [107]. Antenatal SSRI and depression exposure did not predict externalizing 
behaviours; on the other hand, current maternal mood and stress did [106]. In a follow-up 
study, Oberlander et al. [105] explored the effect of antenatal SSRI exposure on 
behavioural development of three-year-olds using Child Behavior Checklist. They found 
that antenatal exposure to SSRIs in combination with concurrent maternal anxiety were 
associated with an increased rate of internalizing behaviour. Externalizing behavior was 
associated with current maternal mood but not antenatal SSRI exposure.  
 
2.3.5.6 Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity 
Disorder (ADHD) 
The evidence for an association between in utero SSRI exposure and ASD in 
children has been inconsistent where some studies supported a positive association [114, 
116, 117, 127] and some did not [113, 118, 119]. All the studies used health care 
databases to select their sample, with sample sizes ranging from 812 to 654,288. A meta-
analysis [128] of 4 case-control studies [116-119] supports the association between in 
utero SSRI exposure and ASD (adjusted OR: 1.81; 95% CI: 1.47-2.24). However, the 
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causality is unknown. Furthermore, the two population cohort studies [113, 114] from the 
same database produced contradictory results.  
Figueroa et al. [112] found that in utero exposure to SSRIs was not associated 
with ADHD using claims-based data. However, a recent large database case-control 
study [120] supported an association between antenatal antidepressant exposure and 
ADHD after controlling for maternal depression (OR: 1.81; 95% CI: 1.22-2.70). 
 
2.3.5.7 Covariates 
Studies examined in this review of literature have controlled a variety of 
confounders, including maternal age [12, 13, 104, 108], maternal IQ [9, 101, 102], 
socioeconomic status [9, 101, 102], education [102, 103, 106], household income [9, 
110], parity [7, 10], weight gain in pregnancy [101, 102], alcohol or tobacco use during 
pregnancy [101, 102], severity and duration of depressive [101, 106, 107] and anxiety 
symptoms [102, 105, 107], duration of treatment [106], presence of postpartum 
depression [12, 102, 105], Apgar score [105], perinatal complications [112], 
breastfeeding status [12], and other maternal medical factors (maternal diabetes, 
hypertension, asthma, and thyroid disorder) [7, 103, 104]. A conceptual model based on 
causality and temporality was constructed from the most commonly used confounders 
and is shown in Appendix B. The model framed the objectives for this study. 
 
2.3.5.8 Summary of Long-Term Developmental Studies  
Some studies indicated that antenatal SSRI use could lead to adverse 
developmental outcomes; however, the clinical relevance of such findings and their 
manifestation later in life remain unclear. In all, the results of numerous studies seem to 
suggest that antenatal SSRI usage does not have a serious detrimental impact on long-
term development of children. However, due to the heterogeneity of study design, 
difference in sample population and size, variation in confounder adjustment, and 
different SSRI usage, it is very difficult to compare results and draw a definite 
conclusion.  
To date only a few studies have compared long-term outcomes of children of 
depressed mothers, with or without SSRI usage during pregnancy, to non-depressed 
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mothers during pregnancy [9-13]. These studies, therefore, were able to compare the 
impact of maternal mood on child development and directly relate this to the effects of 
antenatal SSRI exposure. The remaining studies had women who were not depressed 
during pregnancy and were not using SSRIs as a control group, precluding the separation 
of depression and SSRIs in their outcomes. Therefore, more well-designed studies are 
needed to determine with certainty the long-term effects of antenatal SSRI exposure on 
offspring. 
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Chapter 3: Methods 
3.1 Secondary Data Source: The Prenatal Health Project  
This thesis project used data from a longitudinal cohort study, the Prenatal Health 
Project (PHP). The PHP was designed to understand how prenatal factors impact the 
health and wellbeing of mothers and children before and after pregnancy. 
Pregnant women residing in the London-Middlesex, Canada region were 
recruited, via convenience sampling, in ultrasound clinics in London, Ontario, Canada 
between the periods of 2002 to 2005. Only women 16 years of age and older who carried 
singleton pregnancies between 10 to 22 weeks gestation, spoke English, and lived in 
London-Middlesex region were eligible. Exclusion criteria were high-risk pregnancy and 
known congenital abnormalities. Data were collected throughout the three project phases: 
prenatal, perinatal, and toddler/childhood phase, as described below.  
PHP data collection was approved by the Ethics Review Broad for Health Science 
Research Involving Human Subjects at the University of Western Ontario. The review 
numbers of ethics approval are 08253E and 10787E.  
 
3.1.1 Prenatal Phase 
Women were initially informed about the PHP by ultrasound technicians at their 
scheduled ultrasound appointments. Informed written consent and contact information 
were gathered from women who were interested in participating after speaking with the 
PHP research assistant. Participants were then contacted on the day of the scheduled 
telephone interview to complete the prenatal survey (Appendix C). A trained interviewer 
collected information on socio-demographics factors, maternal lifestyle, dietary intake, 
and medical health. The variables of interest to this thesis are described in more detail in 
Section 3.4.  
 
3.1.2 Perinatal Phase 
Consent for review of perinatal hospital medical records, including delivery room 
charts and maternal and neonatal medical records, had been obtained at recruitment. Data 
on obstetrical risk factors, delivery process and complications, and neonatal health status 
and measurements were abstracted by a trained medical records technician using a Data 
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Abstraction Form. The perinatal variables of interest to this thesis are also discussed in 
detail in Sections 3.4.  
 
3.1.3 Toddler/Childhood Phase 
Women who were recruited at the start of the PHP were contacted again after 
their child was between two to five years of age. Data regarding the mother’s and her 
child’s psychosocial, developmental and nutritional health, and health system use were 
collected over a scripted telephone interview. After completing the postnatal survey, 
mothers were asked to participate in a short survey regarding the child’s development. If 
mothers were interested in participating, the Ages and Stages Questionnaire (ASQ) was 
mailed to the participating mothers. Mothers had the options of submitting the ASQ via 
mail, online website, or over the telephone. Again, specific variables of interest will be 
discussed in Section 3.4. 
 
3.2 Prenatal Health Project Cohort 
The recruitment flow chart is summarized in Figure 3.1. Initially, 3656 women 
were asked to take part in the study and 2761 women agreed to participate. Of those 
women who agreed, 2421 completed the prenatal survey via telephone interview for a 
response rate of 66%. Women with a miscarriage, abortion, neonatal demise, or had 
missing perinatal data were eliminated from the study (n=23). Additionally, 15 women 
were lost to follow-up. Also, 26 women completed the survey twice for different 
pregnancies; therefore one of the duplicates were chosen at random and excluded from 
the sample. Overall, the PHP cohort consisted of 2357 women for whom both the 
prenatal survey data and perinatal chart data were complete. 
At the toddler/childhood phase when the children were two to five-years-old, 
1608 (68%) participants from the original sample participated in the follow-up survey. 
An aspect of the data collection at this phase included completion of a mailed Ages and 
Stages Questionnaire (ASQ). Of those women who participated in the follow-up survey, 
980 (61%) returned the completed ASQ.  
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3.3 Study Groups 
The study groups were identified based on the following prenatal variables: 
prescription medication questions; and the 20-item Centre for Epidemiological Studies 
Depression Scale (CES-D) score.  
The Antidepressant group included mothers who were taking antidepressants 
during pregnancy. Antidepressant use during pregnancy was collected during the prenatal 
telephone survey by asking women to list the prescription medications they took 
regularly at the time. Information on the amount (number of pills and dosage) and the 
frequency of antidepressant use was also available. All antidepressants (SSRIs, SNRIs, 
NDRIs, SARIs, and TCAs) reported were of interest for this thesis due to their shared 
mechanism of action in inhibiting neurotransmitter (serotonin, norephinephrine, and 
dopamine) reuptake at the synapse cleft to prolongs the neurotransmission [51]. The 
selective serotonin reuptake inhibitors (SSRIs) class of antidepressants was especially of 
interest since it is currently the most commonly prescribed and used class of 
antidepressants during pregnancy [59] therefore it was further classified as its own 
subgroup. In brief, women who reported taking antidepressants during pregnancy 
belonged in the Antidepressant group with a subset in the SSRI subgroup. 
The Depressive Symptoms group included mothers with depressive symptoms but 
not taking antidepressants. Maternal depressive symptoms were assessed using the 20-
item CES-D score from the prenatal survey. The CES-D is a commonly used screening 
instrument for depressive symptomology associated with major clinical depression in the 
general population [27] and its use is recommended for the initial evaluation of antenatal 
depressive symptoms [25]. The 20 items inquire how often (<1 day, 1-2 days, 3-4 days, 
or 5-7 days) the participant felt a certain way (feeling of guilt, worthlessness, loss of 
appetite) in the past week with each answer scored on a 4-point Likert scale ranging from 
0 to 3. CES-D scores range from zero to sixty and the higher scores indicate greater 
depressive mood. The cutoff point for possible clinical depression is ≥16 [27]. Therefore, 
women who scored 16 or higher on the CES-D but did not take antidepressants belonged 
in the Depressive Symptoms group.  
 Lastly, the Reference group consisted of women who did not take antidepressants 
during pregnancy and scored lower than 16 on the CES-D.   
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During the postnatal period, specifically when the toddler was >24 months, 
mothers were asked “have you ever been diagnosed as having depression or a mood 
disorder?” Previously diagnosed depression or mood disorder was dichotomized to yes or 
no. To confirm the study group classifications, a cross tabulation was performed between 
this variable and the study groups to compare the frequency distribution.  
 
3.4 Variables of Interest  
The following section of the thesis lists and describes in detail the applicable PHP 
variables established a priori based on literature. Table 3.1 describes the variables on 
maternal characteristics, details on coding, the original questions asked in the survey, and 
when the variables were collected. Additionally, neonatal outcome variables gathered 
during the perinatal phase are described in detail in Section 3.4.4 and Table 3.2. 
Furthermore, Section 3.4.5 describes the developmental outcome measure, specifically, 
Ages and Stages Questionnaire  
 
3.4.1 Baseline Maternal Variables 
Maternal Age 
Participants self-reported their date of birth during the prenatal telephone survey. 
Maternal age at the time of delivery was calculated by subtraction from delivery date. 
The maternal age variable was kept continuous. 
 
Parity 
Parity was measured by asking women the year of each previous pregnancy and 
whether it was a livebirth, stillbirth, or miscarriage/abortion. Parity was defined as the 
number of times a woman has given live birth excluding stillbirth, miscarriages, and fetal 
demises and dichotomized as 0 (nulliparous) or ≥1 (primiparous/multiparous) at the time 
of the current pregnancy.   
 
Education 
Women reported their highest level of education as: elementary school, some high 
school, completed high school, some college or university, college diplomas, university 
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degree, trade school, or other (specified). Education was dichotomized to less 
than/completed high school or greater than high school education. Less than high school 
and completed high school were grouped together due to small cell sizes.  
 
Income  
Income was ascertained by asking women their best estimate of total gross 
income (monetary value in CAN$) from all members of the household before taxes and 
deductions in the past year. Women had the initial option of selecting <$30K or ≥$30K 
then subsequent selection further divides into eight other total gross income amount 
options ranging from <$10,000 to >$80,000. No income, don’t know, refuse to answer 
were also available options and were coded as missing.  
Income was then categorized as <30K (low-income), 30K-80K (middle-income), 
and >80K (upper-middle-income). This categorization is based on a Statistics Canada 
report on low-income-cut-off for urban community size of 100,000 to 499,999 in 2005, 
which was $27,386 and $33,251 before taxes for family household of three and four 
persons, respectively [129]. Conveniently, the cutoff given in the questionnaire was 
consistent with the Statistics Canada cutoff for low-income families.  
 
Marital Status 
Women reported their current marital status as: married, common law (or living 
as married), single/never married, separated/divorced, and widowed. Marital Status was 
then categorized as married, common law, and other (single/never 
married/separated/divorced) in the study. There were no widows in the cohort.  
 
Pre-Pregnancy Body Mass Index 
Body mass index (BMI) was calculated from the participant’s self-reported height 
and weight and was calculated in kg/m2. Women were asked how tall they were without 
shoes and how much they weighed before pregnancy. The standardized cutoff points 
were categorized based on the current WHO categories: <18.5 (underweight); 18.5 to <25 
(normal); 25 to <30 (overweight); and ≥30 (obese) [130]. Underweight and normal 
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weight were grouped together due to the small cell size of underweight category in the 
Antidepressant group.  
 
3.4.2 Prenatal Maternal Variables 
Alcohol use 
Alcohol use during pregnancy was recorded by asking women the number of 
drinks (i.e. glass of wine, beer, or mixed drink) they consumed typically per week at the 
time. The detrimental effects of alcohol consumption during pregnancy are well 
documented and there are no known safe level and time of alcohol consumption during 
pregnancy. Therefore, alcohol usage during pregnancy was dichotomized as yes or no. 
 
Smoking status 
Women were asked “how many cigarettes do you typically smoke each day 
now?” Like alcohol use, there are no safe levels and time of smoking during pregnancy 
so smoking status during pregnancy was categorized as smoker during pregnancy and 
non-smoker during pregnancy.  
 
State Anxiety  
State anxiety quantifies how anxious a person is feeling at a particular moment 
and is measured using the 12-item shortened state version of the State-Trait Anxiety 
Inventory (STAI) [131]. The STAI is one of the most widely researched and administered 
tests for general anxiety. Women were asked how they were feeling in the past week 
regarding their state of anxiety with questions such as “I am calm” and “I am jittery”. 
Responses were recorded using the 4-point Likert scale ranging from 1 to 4: not at all, 
somewhat, moderately so, and very much so. The STAI is a validated and reliable 
screening tool for state anxiety and the higher score indicates higher level of state anxiety 
[131]. Since there are no known cutoffs for STAI scores, the scores were kept continuous 
and converted to standardized score for analysis.  
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Medical Conditions  
 Women were asked whether or not they currently have or had any of the 
following health conditions: heart disease/cardiovascular disease, high blood pressure 
before pregnancy, high blood pressure during pregnancy, diabetes before pregnancy, 
diabetes during pregnancy, asthma, and/or thyroid conditions. Medical conditions of 
interest for this thesis were hypertension before and during pregnancy, diabetes before 
and during pregnancy, asthma, and thyroid conditions. Each medical conditions of 
interest was dichotomized as yes or no.  
 
Weight Gain during Pregnancy 
Weight gain during pregnancy was collected during the perinatal phase from the 
Data Abstraction Forms under summary information on the additional maternal risk 
factors during pregnancy. The underlying data source, the perinatal chart, only classifies 
weight gain as: low ( ≤ 20lbs), appropriate (21lbs to 39lbs), and high weight gain 
(≥40lbs).  
 
3.4.4 Neonatal Outcome Variables 
Preterm birth 
Gestational age was obtained and calculated from the following data sources: 
participant’s self-reported last menstrual period during the prenatal survey and newborn’s 
date of birth; participant’s self-reported gestational period during the ultrasound clinic 
visit and newborn’s date of birth; and infant’s delivery chart (gestational age recorded at 
the time of delivery by medical experts). Gestational age from infant’s hospital chart was 
deemed as the final and correct estimation if the gestational ages from the three data 
sources were within seven days of each other. However, when an estimate from a data 
source was discordant from the other estimates by more than seven days, then all 
available hospital records were reviewed by a medical records technician to investigate 
the possibilities of transcription error. In the case that the estimates were truly different 
by more than 7 days, an OB/GYN reviewed all the hospital charts of the participant and 
determined the best and final gestational age estimate. Gestational age was rounded to the 
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following week if the days were ≥5. Preterm birth is defined as the birth of the baby at 
less than 37 week; therefore it was dichotomized as <37 weeks and ≥37 weeks [7].  
 
Size for Gestational Age 
 Size for gestational age was categorized as small-for-gestational age (birth weight 
≤10th percentile for gestational age), average for gestational age (birth weight >10th to 
90th percentile for gestational age) and large-for-gestational age (birth weight >90th 
percentile for gestational age). The variables required to calculate size for gestational age 
were newborn birth weight, gender, and gestational age. The method for this calculation 
is based on Canadian population standards from Kramer et al. [132].  
 
Apgar Score 
Apgar scores taken at one (Apgar-1) and five (Apgar-5) minutes after birth were 
abstracted from the infant’s hospital chart by trained technicians onto the Data 
Abstraction Form during the perinatal stage. Apgar score assesses the following criteria 
of the newborn: appearance/complexion, pulse rate, reflex irritability/grimace, activity, 
and respiratory effort. Each criterion is scored from 0 to 2, with the overall score ranging 
from 0 to 10. A score of 7 or higher is considered normal therefore Apgar score was 
dichotomized as <7 and ≥7 [84].  
 
Transferred to Specialized Care (TSC) 
Infants transferred to specialized care (TSC) involved those admitted to Pediatric 
critical care unit (PCCU) and neonatal intensive care unit (NICU) after birth. TSC was 
dichotomized to whether newborns were transferred to PCCU/NICU or not.  
 
3.4.5 Developmental Outcome Variables  
Toddler/child development was examined using the age specific ASQ 
administrated by the parents. ASQ is a developmental screening tool that evaluates five 
domains: communication, gross motor, fine motor, problem solving, and personal social 
skills [133]. Each domain has six items pertaining various domain-specific tasks such as 
sentence formation, running, and drawing. The responses for each item are categorized as 
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yes, sometimes, or not yet, each worth ten, five, and zero points, respectively. The 
maximum score for each domain is sixty.  
Conventionally, the score from each domain is compared to an age specific cut-
off point. According to the ASQ manual, a child is considered a “fail” on the ASQ if the 
child scored below but near the cutoff point for just one domain [133]. However, for the 
purpose of this thesis project, the scores from each domain were kept continuous and 
analyzed separately.  
Missing items were handled according to the ASQ manual where missing items 
were imputated with the average score for the specific domain [133]. Parents who 
completed fewer than three items for each domain were removed from the sample. Out of 
the 980 women who returned the ASQ, three ASQs were removed because one ASQ 
could not be linked to the mother’s Study ID, one did not answer any questions, and 
another only answered one question per domain. In addition, 67 toddlers/children were 
preterm infants and were excluded, resulting in 910 toddlers/children analyzed for this 
thesis.  
 
3.6 Statistical Analysis 
3.6.1 Preliminary Inspection and Handling of Dataset 
Preliminary inspection of the dataset was executed using exploratory univariate 
analysis to inspect the variables’ distribution, missing variables, and to ensure all relevant 
variables were cleaned and made sense. Categories of variables with low observed 
frequencies were collapsed together. After the subsequent data cleaning, variables were 
recoded to the desired and intended use described in previous sections. 
 
3.6.2 Descriptive Analysis: Objective 1  
To describe the baseline characteristics of mothers who belonged in the 
Antidepressant, SSRI, Depressive Symptoms, and Reference group for Objective 1, cross 
tabulation analysis was used for categorical variables to report the frequency distribution 
of maternal characteristics described in Section 3.4.1 and 3.4.2. Continuous variables 
were compared among the study groups using descriptive analysis.  
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3.6.3 Descriptive Analysis: Objective 2 
To compare neonatal outcomes among the study groups for Objective 2, bi-
variable cross tabulation analysis was used again to examine the frequency distribution of 
preterm delivery, small-for-gestational age (SGA), large-for-gestational age (LGA), 
Apgar score, and TSC. Due to the imbalanced dataset of the study groups and the small 
sample size of the Antidepressants group and SSRI subgroup, the Morbidity Ratio (MR) 
methodology of Liddell [134] was used to obtain a 95% confidence interval of the rate 
ratio for a Poisson estimate. The MR was the ratio of morbidity (preterm and LGA) 
observed to those expected morbidity rate. The expected morbidity rate was based on 
some reference population, in this case, the Reference group and the Depressive 
Symptoms group.  
The analysis of Apgar scores and TSC were restricted to only infants born at term 
to eliminate the potential of confounding by preterm birth. To calculate the expected 
morbidity rate of the remaining neonatal outcomes (Apgar-1, Apgar-5, and TSC) for the 
MR, the reference population was based only on the Depressive Symptoms group due to 
the low frequency count of adverse events and the similar rates of neonatal outcomes 
among the Reference group and Depressive Symptoms group.  
The two assumptions made were the Observed Counts (O) follows a Poisson 
distribution (random variable with a Poisson distribution) and Expected Counts (E) were 
error-free because it is based on a sufficiently large sample [134]. The linked relationship 
between the Poisson and Chi-square distribution allowed us to use the Chi-square 
distribution to get the critical value to calculate the confidence limits. The following 
equations were used to calculate the lower and upper limits of the 95% confidence 
interval [134].  
 
Lower limit: find 𝜒2L for which Q(𝜒2L∣2O) = 1 – 
1
2
α; 
then E L = 
1
2
𝜒2L and MR L = 
1
2
𝜒2L/E; 
 
Upper limit: find 𝜒2U for which Q(𝜒2U∣2O+2) =  
1
2
α; 
then E U = 
1
2
𝜒2U and MR U = 
1
2
𝜒2 U/E 
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3.6.4 Descriptive Analyses: Objective 3 
The ASQ score for each domain was negatively skewed with a ceiling effect due 
to the normal development of the vast majority of toddlers and children. Therefore to 
compare the long-term child development outcomes (communication, fine motor 
movement, gross motor movement, problem solving, and social/personal skills) of 
toddlers, preschool age children among the study groups for Objective 3, bootstrapping 
method was used where observations from the original datasets were resampled 2000 
times with replacement for each study group’s domains to construct a normal 
distribution. The 95% confidence interval for each study group of each domain was 
calculated from the mean values of the bootstrapped samples using the Bias Corrected 
and accelerated (BCa) method. The BCa method adjusts for the bias in the bootstrap 
estimates using the bias correction and acceleration coefficients hence it is considered the 
improved bootstrap confidence interval [135]. The SAS macro Jackboot was downloaded 
from the SAS website in order to run the bootstrap [136].  
 
3.6.5 Secondary Analyses  
The small sample size of the Antidepressant group prevented an adequate 
multivariable analysis for the investigation of the increased frequency of LGA observed 
in the Antidepressant group. To investigate whether this increased frequency was related 
to antidepressant use or the maternal characteristics of those taking antidepressants, a 
multivariable analysis of the Reference group was performed. The Reference group was 
chosen as a proxy population for the Antidepressant group due to the substantially larger 
sample size and the similar maternal baseline characteristics between the two groups. 
Missing cases for LGA were deleted and missing variables were handled using listwise 
deletion.  
Univariable analysis, specifically Pearson chi-square or Fishers exact test was 
performed to examine the relationship between the individual categorical covariates and 
LGA. The crude relationships between the individual covariates and LGA were examined 
using simple logistic regression. Variables with significance level of p≤0.2 were fitted in 
the multivariable logistic regression model. The backward elimination procedure was 
used with the pre-set significant level of p<0.05. The model included maternal education, 
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income, pre-pregnancy BMI, parity, smoking status during pregnancy, diabetes before 
and during pregnancy, and weight gained during pregnancy. Alcohol use during 
pregnancy was not included in the model due to low cell count. Statistical analyses were 
performed using SAS 9.4.  
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Figure 3.1. Prenatal Health Project Recruitment Flow Chart 
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Table 3.1. Variable definitions of maternal characteristics  
 
Maternal 
Characteristics 
Variables  
Original Question Asked 
in PHP Questionnaire 
Original Format of Variable  Variable Codes 
 
When the Variable 
was Acquired 
(Phase) 
Smoking Status  How many cigarettes do 
you typically smoke each 
day now? 
 
Numeric Value 
 
 
 
0 = Non-smoking 
during pregnancy (0) 
 
1 = Smoked during 
pregnancy (≥ 1) 
Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
Alcohol Use  How many drinks do you 
typically have per week 
now? By drink I mean a 
glass of wine, beer, or a 
mixed drink  
 
Numeric Value  
 
 
 
 
0 = Non-consumer 
during pregnancy (0) 
 
1= Consumer during 
pregnancy (≥ 1) 
Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
Parity –  
Previous live births 
(excluding 
stillbirths, 
miscarriages, and 
fetal demises) 
Please tell me the year that 
each of your previous 
pregnancies ended, and if it 
was a livebirth, stillbirth, 
miscarriage, or abortion. 
Numeric Value (1 to 8) 
 
 
0 = 0 live births  
 
1 ≥ 1 live births 
Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
Education – 
Highest education 
level 
 
 
 
 
 
 
What is your highest level 
of formal education you 
have completed? 
1=Elementary School  
2=Some high school 
3=Completed high school  
4= Some college or university 
5=College diploma 
6=University degree 
7=Trade school  
8=Other 
0 = Did not complete 
high school or 
Completed high school 
 
1 = More than high 
school  
 
Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
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Income –  
Total household 
income 
 
Best estimate of total gross 
income from all member of 
the household before taxes 
and deductions in the past 
year 
 
What is your best estimate 
of the total income of all 
members of your household 
from all sources before 
taxes and deductions for the 
past year? By total income I 
mean total gross income 
from paid employment, 
government assistance, 
student loans, or 
inheritance. 
1 = less than 30K 
2 = greater than or equal to 30K 
3 = less than 15K 
4 = greater than or equal to 15K 
5 = less than 60K 
6 = greater than equal to 60K 
7 = less than 10K 
8 = 10K to $14,900 
9 = 15K to 19,999 
10 = 20K to 29,999 
11 = 30K to 39,999 
12 = 40K to 59,999 
13 = 60K to 79,999 
14 = 80K or more 
15 = no income 
16 = don’t know 
17 = refused to answer 
1 = less than 30k 
2 = 30k-80k 
3 = more than 80K 
 
Refused to 
answer/unclear coded 
as missing  
Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
Marital Status What is your current 
marital status? 
1=Married 
2=Common Law  
3=Single/Never married 
4=Separated/divorced 
5=Widowed 
1 = Married 
2 = Common Law  
3 = Single/Never 
married, 
Separated/divorced 
Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
Maternal Age 
 
 
 
What is your date of birth? Women’s’ date of birth  Continuous Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
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Maternal pre-
pregnancy BMI 
How tall are you without 
shoes? 
 
How much did you weigh 
prior to this pregnancy 
Numeric Variable then 
calculated to BMI (kg/m2) 
1 = <18.5 
(underweight), 18.5-
<25 (normal) 
 
2 = 25-<30 
(overweight) 
 
3 = ≥30 (obese) 
Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
Weight gain during 
pregnancy 
 
 
Other risk factors during 
pregnancy: Other  
 
0=20lbs or less 
1=appropriate 
2=40lbs or more 
 
Comes from Pregnancy risk 
factors in perinatal data set 
(s3_orisk1_details and 
s3_orisk2_details) 
0 = 20lbs or less 
 
1 = appropriate 
 
2 = 40lbs or more 
After birth; Data 
extracted from the 
hospital medical 
records 
(Perinatal Phase) 
Antidepressant Use  
 
 
 
 
Please tell me any OTC and 
prescription medications 
you take regularly now, the 
number of pills or dosage if 
you know it, and how many 
times you take them per 
day  
List of medications  0 = none 
 
1 = Antidepressants   
 
 
Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
Depressive 
Symptoms 
 
 
20-items CES-D 
questionnaire 
Numeric Variable   0 = less than 16 
 
1= equal or greater than 
16 
Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
Anxiety Measure  12 items shorten state 
version of the State-Trait 
Anxiety Inventory (STAI) 
Numeric Variable Continuous  Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
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Diagnosed with 
Depression or Mood 
Disorder in the Past 
Have you ever been 
diagnosed as having 
depression or a mood 
disorder? 
Yes or No Dichotomized ≥24 months old 
follow up 
questionnaire 
(Postnatal Phase) 
Medical Conditions  Pre-existing/Existing 
Health Conditions  
 
I am going to read a list of 
health conditions. For each, 
please say yes if you 
currently have conditions or 
have had the condition in 
the past. If you do not have, 
or have never had the 
condition please respond 
with no. Do you have or 
have you ever had.  
Yes or No: 
 
 
High blood pressure before 
pregnancy 
 
Diabetes before pregnancy  
 
Asthma  
 
Thyroid condition 
Dichotomized  
 
 
 
Telephone interview 
after first visit to 
ultrasound clinic 
(Prenatal Phase) 
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 Table 3.2. Variable definitions of neonatal outcomes  
Neonatal 
outcomes 
Available in Dataset Original Format 
of Variable 
Variable Codes When the Variable 
was Acquired 
(Phase) 
Preterm 
 
 
 
Gestational Age:  
1. Patient’s self-reported  
LMP and baby’s date of birth 
 
2. Gestational age at reported at 
delivery (expert’s medical opinion) 
 
3. Patient’s self-reported gestational at 
recruitment and baby’s date of birth 
 
Preterm Labour: <37 weeks 
Dichotomous 0 = term birth  
 
1 = preterm birth 
After birth; Data 
extracted from the 
hospital medical 
records 
(Perinatal Phase) 
Size for 
Gestational Age 
Gestational Age:  
1. Patient’s self-reported  
LMP and baby’s date of birth 
 
2. Gestational age at reported at 
delivery (expert’s medical opinion) 
 
3. Patient’s self-reported gestational at 
recruitment and baby’s date of birth 
 
Infant Birth weight: 
Grams, Lbs, Oz 
 
Infant Gender:  
Male or Female 
Numeric 0 = 3rd percentile (severe 
SGA)/3rd to 10th percentile 
(moderate SGA) 
 
1 = 10th to 50th percentile 
(AGA)/50th-90th percentile 
(AGA) 
 
2 = >90th percentile (LGA) 
After birth; Data 
extracted from the 
hospital medical 
records 
(Perinatal Phase) 
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Apgar-1  Apgar Score Total  Numeric  1 = less than 7  
 
2 = equal to or greater than 7 
After birth; Data 
extracted from the 
hospital medical 
records 
(Perinatal Phase) 
Apgar-5 
 
 
 
 
 Apgar Score Total  Numeric  1 = less than 7  
 
2 = equal to or greater than 7 
After birth; Data 
extracted from the 
hospital medical 
records 
(Perinatal Phase) 
Transferred to 
Specialized Care 
(TSC) 
Transferred to home, triage/7east, with 
mother/well nursery, PCCU, NICU 
triage, or NICU admission 
Dichotomous  
 
0 = not admitted to NICU 
and PCCU  
 
1 = admission to NICU and 
PCCU 
After birth; Data 
extracted from the 
hospital medical 
records 
(Perinatal Phase) 
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Chapter 4: Results 
4.1 Study Sample  
As presented in Section 3.2, the initial PHP cohort consisted of 2357 women who 
completed the cross sectional survey and consented to the release of perinatal birthing 
information. Only women who completed the CES-D question and prescription drugs 
questions were included for the study. Of the initial cohort, 16 women did not complete 
CES-D Score, one woman did not complete the prescription drugs question, and another 
woman did not complete either; therefore, 18 women were excluded, leaving the sample 
size of 2339 women with both prenatal and perinatal information. Figure 4.1 shows the 
sample size flow of the study groups in the Prenatal, Perinatal, and Postnatal Stages. The 
sample size for each study group at the outset (prenatal) was as followed:  
 44 women (1.88%) reported antidepressant use during the pregnancy 
(Antidepressant group);  
 32 women (1.37%) were on SSRIs (SSRI subgroup);  
 421 women (18.00%) reported clinically significant depressive symptoms 
without antidepressant intervention (Depressive Symptoms groups);  
 1874 women (80.12%) did not have clinically significant depressive 
symptoms nor report antidepressant use (Reference group).  
 
4.2. Antidepressant Use 
The specific antidepressants used during pregnancy are presented in Table 4.1. Of 
the 44 women who reported antidepressant use during pregnancy, 32 (72.7%) were 
SSRIs, five (11.4%) were SNRIs, four (9.1%) were on TCAs, two (4.6%) on NDRIs and 
one (2.3%) on SARI. Further data on the amount and frequency of use is presented in 
Table 4.2. The dose for all women was within the recommended range and two women 
were on the maximum recommended dose: sertraline (SSRI) – 200mg/day and 
nefazondone (SARI) – 600mg/day. All women reported having taken antidepressants 
daily except for three women: one took venlafaxine (SNRI) every 2-3 days, one took 
sertraline daily if she could afford it, and one took fluoxetine (SSRI) every other day.  
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4.3 Characteristics of the Study Groups  
Maternal characteristics are presented in Table 4.3, stratified by study group 
membership. Given the imbalanced sample size distribution of the study groups and the 
small sample size of the Antidepressants group and SSRI subgroup, we were left to 
describe the maternal characteristics of the study groups by comparing frequency 
distribution and means.  
To begin, women in the Antidepressant group and SSRI subgroup were more 
likely to be overweight or obese, where the Antidepressant group had the largest 
percentage (30.2%) of overweight (BMI 25 - <30kg/m2) women before pregnancy and 
the SSRI subgroup had the largest percentage (25%) of obese (BMI ≥30kg/m2) women 
before pregnancy. The Antidepressant group and SSRI subgroup were also more likely to 
be primiparous/multiparous (61.4% and 56.3%, respectively), whereas the percentages of 
nulliparous and primiparous/multiparous for both Reference group and Depressive 
Symptoms groups are close to equal at 50%.  
Furthermore, women in the Antidepressant group and SSRI subgroup were older, 
more likely to be married, more likely to have higher than a high school education, and 
more affluent relative to women in the Depressive Symptoms group. Specifically, the 
mean maternal age of women in the Antidepressant group and Depressive Symptoms 
group were about 31 (standard deviation [SD] of 4.4) and 28 (standard deviation [SD] of 
5.5), respectively. The rates of women who had an education higher than high school in 
the Antidepressant group and SSRI subgroup were 86.4% and 84.4%, respectively, 
compared to 67.7% of women in the Depressive Symptoms group. 
The majority (75%) of women in the Antidepressant group and SSRI subgroup 
were married compared to 56.4% in the Depressive Symptoms group.  Women in the 
Depressive Symptoms group were more likely to be single/never married, or 
separated/divorced (20%) compared to other study groups (3.1% - 6.8%).  
Women in the Antidepressant group and SSRI subgroup were also more affluent 
such that 36.4% and 37.5% had an annual household income greater than $80,000 
compared to 24.8% of women in the Depressive Symptoms group. Furthermore, women 
in the Depressive Symptoms group were more likely to report an annual household 
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income of less than $30,000 (25.6%) compared to the Antidepressant group (18.2%) and 
SSRI subgroup (15.6%).  
 The demographic characteristics (maternal age, income, marital status, and 
education) of women in the Antidepressant group and SSRI subgroup were comparable to 
women in the Reference group. Women in the Reference group were the most affluent 
and only 8.5% of women reported an annual household income of less than $30,000.  
Notably, the women in the Depressive Symptoms group were more likely to 
display high-risk behaviours during pregnancy. Women in the Depressive Symptoms 
group had higher rate of smoking (22.5%) and alcohol consumption (4.5%) during 
pregnancy compared to the other groups (smokers: 7.8%-11.4%; alcohol use: 1.8%-
3.1%). Furthermore, women in the Depressive Symptoms group were the most likely to 
gain 40 pounds or more during pregnancy (15.7%) and the SSRI subgroup had the fewest 
women gaining 40 pounds or more during (9.4%). Other than that, weight gain during 
pregnancy was relatively comparable in all groups.  
Very few women in the study gained 40lbs or more during pregnancy, had 
hypertension, diabetes, and thyroid condition before and/or during pregnancy with cell 
counts at ≤5 in the Antidepressant group and SSRI subgroup. Women in all study groups 
had similar rates of hypertension before and/or pregnancy (9.3%-11.4%). Both the 
Antidepressant group and SSRI subgroup were more likely to have a thyroid condition 
(6.8% and 9.4%) and diabetes (4.5% and 6.3%); however, the cell sizes were too small to 
make further inferences. The occurrence of asthma was more likely for women in the 
Antidepressant group (25%) compared to other study groups. The mean (SD) state 
anxiety STAI raw scores for the Antidepressant, SSRI, Depressive Symptoms, and 
Reference group were 23.3 (7.2), 23.2 (7.0), 27.5 (5.5), and 19.4 (4.4), respectively.  
For the confirmation of the classification of study groups, it was found that high 
percentages (87.5% and 94.1%) of women in the Antidepressant group and SSRI 
subgroup were diagnosed with depression or mood disorder in the past. Whereas 31.9% 
and 11.7% of women in the Depressive Symptoms group and Reference group were 
diagnosed with depression or mood disorder in the past. 
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4.4 Study Groups and Outcomes 
4.4.1 Neonatal Outcomes 
The frequency distributions for preterm birth, SGA, and LGA are shown in Table 
4.4a. The rate of preterm birth and LGA was higher in the Antidepressant group (preterm: 
13.6%; LGA: 32.6%) and the SSRI subgroup (preterm: 18.8%; LGA: 32.3%) than the 
Depressive Symptoms (preterm: 7.6%; LGA: 12.0%) and Reference group (preterm: 
5.3%; LGA: 12.6%). SGA infants were not observed in the Antidepressant group and 
SSRI subgroup. 
Table 4.4b presents the expected count of preterm birth, SGA, and LGA (based on 
the rate of the Reference group), the MR of observed/expected, and the 95% Poisson 
confidence interval of the rate ratio. There was a significantly higher count of preterm 
births in the SSRI subgroup when the expected rate was based on the rate of the 
Reference group (MR=3.4, 95% CI: 1.3-7.7). The count of LGA was also significantly 
higher in the Antidepressant group (MR=2.6, 95% CI: 1.4-4.4) and SSRI subgroup 
(MR=2.6, 95% CI: 1.2-4.7). When using the rate based on the Depressive Symptoms 
group, the number of LGA was significantly higher in both the Antidepressant (MR=2.6, 
95% CI: 1.4-4.4) group and SSRI (MR=2.7, 95% CI: 1.3-5.0) subgroup as presented in 
Table 4.4c.  
The frequency distributions for Apgar-1, Apgar-5, and TSC of infants born at 
term are shown in Table 4.5. Preterm newborns (n=138) were excluded; therefore, the 
sample sizes of the study groups of infants born at term were reduced to: 38 in the 
Antidepressant group, 26 in the SSRI subgroup, 389 in the Depressive Symptoms group, 
and 1774 in the Reference group. The number of newborns in the Antidepressant group 
and SSRI subgroup who were transferred to specialized care units and scored lower than 
seven on the Apgar at one and five minutes were very diminutive at less than five 
observations. However, infants in the Antidepressant group and SSRI subgroup were 
more likely to score less than seven on the Apgar at one and five minutes relative to the 
Depressive Symptoms and Reference group. The small cell sizes make it difficult to show 
significant increased risks when the expected rate was based on Depressive Symptoms 
group. The rates of TSC were comparatively similar for all the study groups. 
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4.4.2 Developmental Outcomes 
 Table 4.6 presents the bootstrapped mean and the 95% Bootstrap Bias Corrected 
and accelerated (BCa) Confidence Interval of the ASQ score for each domain. Due to 
loss to follow up (n=749), unwillingness to participate in the ASQ survey (n=628), 
removal of the returned incomplete ASQ survey (n=3), and the elimination of 
toddler/children who were born preterm (n=67), the sample sizes of the study groups 
were reduced to 15 in the Antidepressant group, 9 in the SSRI subgroup, 120 in the 
Depressive Symptoms group, and 775 in the Reference group.  
Toddlers/children of the Reference group and the Depressive Symptoms groups 
had very similar bootstrapped mean scores and overlapping confidence intervals across 
all domains. 
The Antidepressant group had a lower bootstrapped mean score for the 
communication (54.8; 95% CI: 49.2-58.6), gross motor (53.7; 95% CI: 45.2-58.9), fine 
motor (49.9; 95% CI: 40.7-55.2), and personal/social skills (54.3; 95% CI: 49.3-58.3) 
domain compared to the Depressive Symptoms and Reference groups. The SSRI 
subgroup had the lowest bootstrapped mean score for the communication (52.4; 95% CI: 
45.8-58.1), gross motor (49.4; 95% CI: 36.5-57.1), fine motor (44.4; 95% CI: 32.2-56.0), 
and personal/social skills (52.2; 95% CI: 45.3-58.2) domains compared to all the groups. 
Due to the small sample size of the Antidepressant group and SSRI subgroup, the 95% 
Bootstrap Bias Corrected and accelerated (BCa) Confidence Intervals were very wide and 
overlapped in all the study groups for all development domains and further analysis and 
inference was not possible.  
 
4.5 Secondary Analysis on the Reference Group 
Given an increased frequency of LGA in the Antidepressant group, it was of 
interest to investigate whether this increased frequency was due to the Antidepressant, 
per se, or the maternal characteristics of those taking antidepressants. The small sample 
sizes precluded a full multivariable analysis of this question. However, the role of various 
covariates in the risk of LGA in the Reference group was investigated to explore 
inferences related to maternal characteristics.  
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Table 4.7 presents the frequency distribution and the univariable association 
between maternal characteristics and LGA using Pearson chi-square test and Fisher exact 
test. The sample size used for this analysis was 1854 after removing 20 missing cases 
from the size of gestational age variable. The results of the univariable and multivariable 
logistic regression analysis are shown in Table 4.8. The variables that had p≤0.2 in 
univariable analysis, thus included in the multivariable logistic regression model, were: 
education level, annual income, pre-pregnancy BMI, parity, smoking status during 
pregnancy, diabetes before and/or during pregnancy, and weight gain during pregnancy. 
Although alcohol use during pregnancy had a p-value of 0.1227, it was not included in 
the model due to small cell size.  
The final sample size of the multivariable logistic regression model was 1684. 
The variables that stayed significantly associated (p<0.05) to LGA in the model were pre-
pregnancy BMI, parity, smoking during pregnancy, diabetes before and/or during 
pregnancy, and weight gained during pregnancy.   
Compared to women whose pre-pregnancy BMI was <25 (normal or 
underweight), women whose pre-pregnancy BMI was ≥30 (obese) had increased odds of 
having infants born LGA (OR=2.05, 95% CI: 1.36-3.08). Women who had a pre-
pregnancy BMI of 25 to <30 also had increased odds of having infants born LGA 
(OR=1.58, 95% CI: 1.12-2.24) compared to the infants of women whose pre-pregnancy 
BMI was <25 (normal or underweight). 
Women who were primiparous or multiparous were more likely to have LGA 
infants compared to women who were nulliparous (OR=1.51, 95% CI: 1.12-2.04). 
Women who smoked during pregnancy were less likely to have LGA infants compared to 
women who did not smoke during pregnancy (OR=0.47, 95% CI: 0.23-0.96). 
Furthermore, women who had diabetes before and/or during pregnancy had an increased 
risk of having LGA infants compared to women who did not have diabetes before and/or 
during pregnancy (OR=2.79, 95% CI: 1.43-5.46).  
Lastly, compared to women who had appropriate weight gain during pregnancy 
(>20 to <40lbs), women who gained 40lbs or more had an increased risk of delivering 
LGA infants (OR=2.23, 95% CI: 1.51-3.30).  
49 
 
 
 In the model diagnostic, the Hosmer and Lemeshow goodness-of-fit test showed 
that the multivariable logistic regression model was a good fit (chisq: 3.15, df: 6, 
p=0.7901). The pseudo R-square and max-rescaled pseudo R-square for the model were 
0.0290 and 0.0544, respectively. The diagnostic test for multicollinearity indicated that it 
was not a concern since all the predictor variables had variance inflation factor of lower 
than two. 
 
4.6 Summary of Findings  
In regards to Objective 1, our findings suggested that women on antidepressants 
were more likely to be overweight and obese before pregnancy, primiparous or 
multiparous, and asthmatic in comparison to the other study groups. Furthermore, women 
displaying depressive symptoms were younger, less likely to have more than high school 
education, less likely to be married, less financially well-off, more likely to display 
harmful behaviours during pregnancy, and had the highest STAI raw scores compared to 
the other study groups.  
In regards to Objective 2, the results from the univariable analysis suggested that 
infants exposed to antidepressants and SSRIs in utero were more likely to be LGA 
compared to the infants whose mothers belonged to the Depressive Symptoms or 
Reference groups. Based on the multivariable logistic regression of the Reference group, 
women who were primiparous/multiparous, overweight and obese before pregnancy, 
diabetic before and/or during pregnancy, and had weight gain of 40lbs or more during 
pregnancy had an increased odd of having LGA infants.  
In regards to Objective 3, toddlers/preschoolers of women who were on SSRIs 
had lowest mean score in the communication, fine and gross motor movement, and 
personal/social skills domain of the ASQ compared to the other groups.    
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Figure 4.1. Sample flow for the Prenatal, Perinatal, and Postnatal Phases: the Flow 
Pertains to the Analyses for this Thesis Project. 
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Table 4.1. Antenatal antidepressant use 
Antidepressants (n=44) Frequency (%) 
SSRIs (n=32)           
Citalopram (Celexa) 
Fluvoxamine (Luvox) 
Paroxetine (Paxil) 
Sertraline (Zoloft) 
Fluoxetine (Prozac) 
Unknown                                    
 
5 (11.4%) 
1 (2.3%) 
9 (20.4%) 
9 (20.4%) 
7 (15.9%) 
1 (2.3%) 
SNRIs (n=5) 
       Venlafaxine (Effexor) 
 
5 (11.4%) 
NDRIs (n=2) 
  Bupropion (Wellbutrin) 
           Bupropion (Zyban) 
 
1 (2.3%) 
1 (2.3%) 
SARIs  (n=1) 
     Nefazodone (Serzone) 
 
1 (2.3%) 
TCAs (n=4) 
                     Amitriptyline 
 
4 (9.1%) 
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Table 4.2. Amount and frequency of antenatal antidepressant use 
Antidepressants    Count – Amount/day 
SSRIs 
              Citalopram (Celexa)              
 
5 – 20mg/day 
      Fluvoxamine (Luvox)           1 – 50mg/day 
Paroxetine (Paxil)                 1 – 10mg/day 
6 – 20mg/day 
1 – 30mg/day 
1 – 40mg/day                                                                                                                                          
Sertraline (Zoloft)                 1 – 25mg/day 
1 – 50mg/day 
5 – 100mg/day 
2 – 200mg/day1                                                                           
Fluoxetine (Prozac)              1 – 10mg every other day 
2 – 20mg/day  
3 – 40mg/day 
1 – 60mg/day 
Unknown    1 – 75mg/day 
SNRIs 
Venlafaxine (Effexor)           
 
1 – 20mg every 2-3 days 
2 – 75mg/day  
1 – 150mg/day 
1 – 250mg /day 
NDRIs 
Bupropion (Wellbutrin)      
 
1 – 150mg/day 
Bupropion (Zyban)               1 – 2 tablets/day 
SARIs  
Nefazodone (Serzone)         
 
1 – 600mg/day1 
TCAs 
Amitriptyline                          
 
1 – 20mg/day 
2 – 25mg/day 
1 – 60mg/day 
 1Maximum recommended dose
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Table 4.3 Maternal characteristics in the four study groups: exposed to any 
antidepressant, exposed to SSRIs, exposed to maternal depressive symptoms without 
antidepressant use, and unexposed to either depressive symptoms or antidepressants 
(Total N=2339)  
 
Maternal Characteristics Antidepressant 
Use 
(n=44) 
SSRI 
Use 
(n=32) 
Depressive 
Symptoms, 
no 
Antidepressant 
Use   (n=421) 
Neither 
Depressive 
Symptoms nor 
Antidepressant 
Use (n=1874) 
Baseline Maternal 
Variables 
Frequency (%) 
Parity (n=2339) 
                                  0 
                                  ≥ 1 
 
17 (38.6%) 
27 (61.4%) 
 
14 (43.8%) 
18 (56.2%) 
 
214 (50.8%) 
207 (49.2%) 
 
927 (49.5%) 
947 (50.5%) 
Education Level (n=2339) 
                  ≤High School 
                     >High School 
 
6 (13.6%) 
38 (86.4%) 
 
5 (15.6%) 
27 (84.4%) 
 
136 (32.3%) 
285 (67.7%) 
 
268 (14.3%) 
1606 (85.7%) 
Annual Income* (n=2189) 
                        <30K 
                        30K-80K 
                                  >80K 
 
 
8 (18.2%) 
20 (45.4%) 
16 (36.4%) 
 
 
5 (15.6%) 
15 (46.9%) 
12 (37.50%) 
 
95 (25.6%) 
184 (49.6%) 
92 (24.8%) 
50 missing 
 
150 (8.5%) 
893 (50.3%) 
731 (41.2%) 
100 missing 
Marital Status* (n=2338) 
                               Married 
                      Common-law 
                                  Other 
 
 
33 (75.0%) 
8 (18.2%) 
3 (6.8%) 
 
 
24 (75.0%) 
7 (21.9%) 
1 (3.1%) 
 
 
237 (56.4%) 
99 (23.6%) 
84 (20.0%) 
1 missing 
 
1518 (81.0%) 
259 (13.8%) 
97 (5.2%) 
 
Pre-Pregnancy BMI* 
(n=2251) 
 Underweight (<18.5) and  
            Normal (18.5 - <25) 
       Overweight (25 - <30) 
                        Obese (≥30) 
 
 
 
21 (48.8%) 
13 (30.2%) 
9 (20.9%) 
1 missing 
 
 
 
17 (53.1%) 
7 (21.9%) 
8 (25.0%) 
 
 
 
 
247 (62.5%) 
82 (20.8%) 
66 (16.7%) 
26 missing 
 
 
 
1197 (66.0%) 
394 (21.7%) 
222 (12.3%) 
61 missing 
 Mean (SD) 
Maternal Age (n=2339) 31.0 (4.4) 30.8 (4.3) 28.3 (5.5) 30.3 (4.8) 
Prenatal Maternal 
Variables 
Frequency (%) 
Smoked During 
Pregnancy* (n=2317) 
5 (11.4%) 3 (9.4%) 94 (22.5%) 
3 missing 
145 (7.8%) 
19 missing 
Alcohol Use During 
Pregnancy* (n=2316) 
1 (2.3%) 1 (3.1%) 19 (4.5%) 
3 missing 
34 (1.8%) 
20 missing 
Hypertension Before 
and/or During Pregnancy 
(n=2339) 
5 (11.4%)  
 
3 (9.4%) 
 
44 (10.4%) 
 
174 (9.3%) 
 
Diabetes Before and/or 
During Pregnancy 
(n=2339)  
2 (4.5%) 
 
2 (6.3%) 
 
18 (4.3%) 
 
55 (2.9%) 
 
Asthma (n=2330)* 
 
11 (25.0%) 
 
5 (15.6%) 
 
78 (18.6%) 
2 missing 
263 (14.1%) 
7 missing 
Thyroid Condition 
(n=2339) 
3 (6.8%) 3 (9.4%) 15 (3.6%) 86 (4.6%) 
54 
 
 
Diagnosed with 
Depression or Mood 
Disorder in the Past** 
(n=1345) 
                                      Yes 
                                       No 
 
 
 
 
21 (87.5%) 
3 (12.5%) 
 
 
 
 
16 (94.1%) 
1 (5.9%) 
 
 
 
 
66 (31.9%) 
141 (68.1%) 
 
 
 
 
130 (11.7%) 
984 (88.3%) 
Weight Gain during 
Pregnancy (n=2339) 
                      20lbs or less 
                        Appropriate  
                     40lbs or more 
 
 
0 
39 (88.6%) 
5 (11.4%) 
 
 
0 
29 (90.62%) 
3 (9.38%) 
 
 
22 (5.22%) 
333 (79.10%) 
66 (15.68%) 
 
 
68 (3.6%) 
1592 (85.0%) 
214 (11.4%) 
 Mean (SD) 
State Anxiety (STAI Raw 
Score) (2337) 
 
23.3 (7.2) 
 
23.2 (7.0) 
 
27.5 (5.5) 
1 missing 
 
19.4 (4.4) 
1 missing 
*Calculated percentage does not include missing observations 
** Percentage based on postnatal data 
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Table 4.4a Neonatal outcomes in the four study groups: exposed to any antidepressant, exposed to SSRIs, exposed to maternal 
depressive symptoms without antidepressant use, and unexposed to either depressive symptoms or antidepressants (Total 
N=2339)  
 
  Antidepressant 
Use 
(n = 44) 
SSRI 
Use 
(n = 32) 
Depressive Symptoms, 
no 
Antidepressant 
Use   (n = 421) 
Neither Depressive Symptoms nor 
Antidepressant 
Use 
(n = 1874) 
 Frequency (%) 
Gestational Age    
Preterm 
 
6 (13.6%) 
 
6 (18.8%) 
 
32 (7.6%) 
 
100 (5.3%) 
Size for Gestational Age*   
  SGA 
  LGA 
 
0 (0)  
14 (32.6%)  
1 missing 
 
0 (0) 
10 (32.3%)  
1 missing 
 
30 (7.2%) 
50 (12.0%) 
6 missing 
 
126 (6.8%) 
234 (12.6%) 
20 missing 
*Calculated percentage does not include missing observations 
 
Table 4.4b The expected count in each study group (reference = unexposed to either depressive symptoms or antidepressants), 
the ratio of observed/expected and the 95% Poisson confidence interval of the rate ratio of observed/expected 
 
 Antidepressant 
Use 
SSRI 
Use 
Depressive Symptoms,  
no 
Antidepressant 
Use   
Preterm                           expected number 
observed/expected (CI) 
2.3 
2.6 (1.0, 5.7) 
1.7 
3.5 (1.3, 7.7)* 
22.5 
1.42 (1.0, 2.0) 
LGA                                expected number 
  observed/expected (CI) 
5.4 
2.6  (1.4, 4.4)* 
3.9 
2.56 (1.2, 4.7)* 
52.4 
1.0 (0.7, 1.3) 
Note: expected is based on the rate in the No Depressive Symptoms/No Antidepressant group 
*statistically significant 
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 Table 4.4c The expected count in each study group (reference = exposed to depressive symptoms and unexposed to 
 antidepressants), the ratio of observed/expected and the 95% Poisson confidence interval of rate ratio of 
 observed/expected 
 
 Antidepressant 
Use 
SSRI 
Use 
Preterm                          expected number 
observed/expected (CI) 
3.3 
1.8 (0.7, 4.0) 
2.4 
2.5 (0.9, 5.4) 
LGA                               expected number 
observed/expected (CI) 
5.3 
2.6  (1.4, 4.4)* 
3.7 
2.7 (1.3, 5.0)* 
Note: expected is based on the rate in the Depressive Symptoms/No Antidepressant group  
*statistically significant  
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Table 4.5a Neonatal outcomes of term infants in the four study groups: exposed to any antidepressant, exposed to SSRIs, 
exposed to maternal depressive symptoms without antidepressant use, and unexposed to either depressive symptoms or 
antidepressants (Total N=2201)  
 
 Antidepressants 
Use 
(n = 38) 
SSRI Use 
(n = 26) 
Depressive Symptoms, 
no 
Antidepressant 
Use   (n = 389) 
Neither Depressive 
Symptoms nor 
Antidepressant 
Use 
(n = 1774) 
 Frequency (%) 
Apgar-1* (n=2132) 
                                <7 
                               ≥7 
 
4 (11.4%)    
31 (88.6%) 
3 missing  
 
4 (17.4) 
19 (82.6) 
3 missing 
 
24 (6.5) 
346 (93.5) 
19 missing 
 
143 (8.3) 
1584 (91.7) 
47 missing 
Apgar-5* (n=2132) 
                                <7 
                               ≥7 
 
1 (2.9) 
34 (97.1) 
3 missing 
 
1 (4.4) 
22 (95.6) 
3 missing 
 
1 (0.3) 
370 (99.7) 
18 missing 
 
8 (0.5) 
1718 (99.5) 
48 missing 
TSC* (n=2198) 
                              Yes 
                               No 
 
2 (5.3) 
36 (94.7) 
 
1 (3.8) 
25 (96.2) 
 
13 (3.3) 
376 (96.7) 
 
42 (2.4) 
1729 (97.6) 
3 missing 
   *Calculated percentage does not include missing observations 
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Table 4.5b The expected count in each exposure group (reference = exposed to depressive symptoms and unexposed to 
antidepressants), the ratio of observed/expected, and the 95% Poisson confidence interval of rate ratio of observed/expected 
 
 Antidepressant 
Use 
SSRI 
Use 
Apgar-1 <7                         expected number 
observed/expected (CI) 
2.4 
1.7 (0.5, 4.2) 
1.5 
2.7 (0.7, 6.9) 
Apgar-5 <7                         expected number 
observed/expected (CI) 
0.1 
10.6  (0.3, 59.0) 
0.1 
16.1 (0.4, 89.7) 
TSC                                    expected number 
observed/expected (CI) 
1.3 
1.6 (0.2, 5.7) 
0.9 
1.15 (0.03, 6.4) 
Note: expected is based on the rate in the Depressive Symptoms/No Antidepressant group 
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Table 4.6 Mean and the 95% Bootstrap Bias Corrected and accelerated (BCa) Confidence Interval of ASQ Scores from five 
domains of term toddlers in the four study groups: exposed to any antidepressant, exposed to SSRIs, exposed to maternal 
depressive symptoms without antidepressant use, and unexposed to either depressive symptoms or antidepressants  
(Total N=910) 
 
ASQ Domains Antidepressants 
(n = 15) 
SSRIs 
(n = 9) 
Depressive 
Symptoms/No 
Treatment Exposure 
(n = 120) 
No Depressive 
Symptoms (n = 775) 
 Bootstrap Mean (95% Bootstrap BCa Confidence Interval) 
Communication (n=909) 54.8 (49.2, 58.6) 
 
52.4 (45.8, 58.1) 
 
55.3 (53.6, 56.9) 
 
56.0 (55.4, 56.5) 
1 missing 
Gross Motor (n=909) 53.7 (45.2, 58.9) 
 
49.4 (36.5, 57.1) 
 
55.2 (52.5, 56.9) 
 
56.4 (55.8, 56.8) 
1 missing 
Fine Motor (n=906) 49.9 (40.7, 55.2) 
 
44.4 (32.2, 56.0) 
 
50.6 (47.8, 53.0) 
1 missing 
51.4 (50.6, 52.3) 
3 missing 
Problem Solving (n=908) 57.3 (47.0, 60.0) 
 
56.7 (44.7, 60.0) 
 
55.2 (53.0, 57.0) 
 
55.0 (54.4, 55.5) 
2 missing 
Personal/Social (n=908) 54.3 (49.3, 58.3) 52.2 (45.3, 58.2) 55.5 (52.9, 57.0) 55.1 (54.5, 55.6) 
2 missing 
 
  
60 
 
 
Table 4.7 LGA frequency by maternal characteristics (n=1854) 
  
Categorical Maternal 
Characteristics 
LGA Frequency (%) P-value 
Education Level (n=1854)                                 
≤High School      
 >High School      
 
27/265 (10.2%) 
207/1589 (13.0%) 
 
0.1977a 
Annual Income (n=1755) 
                                   <30K   
                                   30K-80K  
                                  >80K  
 
15/148 (10.1%) 
124/886 (14.0%) 
82/721 (11.4%) 
 
 
0.1854a 
Marital Status (n=1854) 
                                  Married  
                                 Common-law   
                                  Other  
 
195/1502 (13.0%) 
28/255 (11.0%) 
11/97 (11.3%) 
 
0.6235a 
Pre-Pregnancy BMI (n=1793) 
             Underweight (<18.5) and  
                      Normal (18.5 - <25) 
                   Overweight (25 - <30) 
                                      Obese 
(≥30) 
 
 
123/1184 (10.4%) 
63/388 (16.2%) 
40/221 (18.1%) 
 
 
0.0003a 
Parity (n=1854) 
                                  0 
                                  ≥ 1 
 
97/915 (10.6%) 
137/939 (14.6%) 
 
0.0097a 
Smoked During Pregnancy  
(n=1835) 
Yes  
No  
 
 
9/143 (6.3%) 
223/1692 (13.2%) 
 
 
0.0173a 
Alcohol Use During Pregnancy 
(n=1834) 
Yes  
No 
 
 
1/34 (2.9%) 
229/1800 (12.7%) 
 
 
0.1138b  
 
Hypertension Before and/or 
During Pregnancy (n=1848) 
Yes  
No 
 
 
23/171 (13.4%) 
210/1677 (12.5%) 
 
 
0.7277a 
Diabetes Before and/or During 
Pregnancy (n=1854) 
Yes  
No 
 
 
16/53 (30.2%) 
218/1801 (12.1%) 
 
 
<.0001a 
Asthma (n=1847) 
Yes  
No 
 
35/261 (13.4%) 
197/1586 (12.4%) 
 
 
0.6551a 
Thyroid Condition (n=1854) 
Yes  
No 
 
8/84 (9.5%) 
226/1770 (12.8%) 
 
0.3816a 
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Weight Gain during Pregnancy 
(n=1854) 
                                  20lbs or less   
                                  Appropriate  
                                 40lbs or more 
 
 
6/66 (9.1%) 
185/1575 (11.8%) 
43/213 (20.2%) 
 
 
0.0016a 
Numeric Maternal 
Characteristics 
LGA Frequency (%)  
Mean (SD) 
Non LGA Freq 
(%) 
Mean (SD) 
State Anxiety (Standardized) 
(1853) 
234 (12.6%) 
0 (1) 
1619 (87.4%) 
0 (1) 
Maternal Age (n=1854) 234 (12.6%) 
30.6 (4.7) 
1620 (87.4%) 
30.3 (4.9) 
 aPearson chi-square test 
 bFisher exact test 
 Note: significant level ≤0.2 
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Table 4.8 Univariable and multivariable logistic regression of maternal characteristics 
and LGA 
 
Categorical Maternal 
Characteristics 
OR (95% Wald CI) [p-value] 
 Univariable  Multivariable (n=1684) 
Education Level                             
≤High School   
 >High School  
0.76 (0.50, 1.16) [0.1992] 
[reference] 
entered 
Annual Income  
                                   <30K  
                              30K-80K  
                                   >80K 
 
0.88 (0.49, 1.57) [0.6637] 
1.27 (0.94, 1.71) [0.1184] 
[reference] 
 
entered 
Marital Status 
                                  Married  
Common-law 
                                  Other 
 
[reference] 
0.83 (0.54, 1.26) [0.3752] 
0.86 (0.45, 1.64) [0.6401] 
 
not entered 
Pre-Pregnancy BMI  
Underweight (<18.5) and 
Normal (18.5 - <25) 
Overweight (25 - <30) 
Obese (≥30) 
 
 
[reference] 
1.67 (1.20, 2.32) [0.0021] 
1.91 (1.29, 2.82) [0.0012] 
 
 
[reference] 
1.58 (1.12, 2.24) [0.0093]* 
2.05 (1.36, 3.08) [0.0006]* 
Parity  
                                  0  
                                  ≥ 1 
 
[reference] 
1.44 (1.09, 1.90) [0.0100] 
 
[reference] 
1.51 (1.12, 2.04) [0.0072]* 
Smoked During Pregnancy  
Yes 
No  
 
0.44 (0.22, 0.88) [0.0205] 
[reference] 
 
0.47 (0.23, 0.96) [0.0376]* 
[reference] 
Alcohol Use During Pregnancy 
Yes  
No  
 
0.21 (0.03, 1.53) [0.1227] 
[reference] 
 
not entered 
Hypertension Before and/or 
During Pregnancy  
Yes  
No  
 
 
1.09 (0.68, 1.72) [0.7277] 
[reference] 
 
not entered 
Diabetes Before and/or During 
Pregnancy 
Yes  
No  
 
 
3.14 (1.72, 5.74) [0.0002] 
[reference] 
 
 
2.79 (1.43, 5.46) [0.0028]* 
[reference] 
Asthma  
Yes  
No  
 
1.09 (0.74, 1.61) [0.6552] 
[reference] 
 
not entered 
Thyroid Condition  
Yes  
No  
 
0.72 (0.34, 1.51) [0.3843] 
[reference] 
 
not entered 
 Weight Gain during Pregnancy  
                                20lbs or less 
               Appropriate  
                              40lbs or more 
 
0.75 (0.32, 1.76) [0.5113] 
[reference] 
1.90 (1.32, 2.76) [0.0006] 
 
0.68 (0.28, 1.65) [0.3973] 
[reference] 
2.23 (1.51, 3.30) [<.0001]* 
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State Anxiety (Standardized) 1.00 (0.87, 1.15) [0.9743] not entered 
Maternal Age 1.02 (0.99, 1.05) [0.2534] not entered 
*statistically significant level <0.05 
Note: Alcohol use during pregnancy not entered into model due to small cell 
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Chapter 5: Discussion 
The purpose of this thesis study is to investigate the effects of maternal 
antidepressant use, with special focus on SSRI use during pregnancy on neonatal and 
long-term child developmental outcomes. Specifically, the first objective is to describe 
the baseline characteristics of pregnant women who belonged in the following study 
groups: those who took antidepressants during pregnancy (Antidepressant group); those 
who took SSRIs during pregnancy (SSRIs subgroup); those who have elevated depressive 
symptoms during pregnancy but not taking antidepressants (Depressive Symptoms 
group); and those who do not have elevated depressive symptoms and do not take 
antidepressants during pregnancy (Reference group). The second objective is to compare 
the neonatal outcomes, specifically, preterm delivery, small-for-gestational age (SGA), 
large-for-gestational age (LGA), Apgar scores at one and five minutes, and NICU 
admission among newborns whose mothers belonged to the study groups. The third 
objective is to compare the long-term development of toddlers and preschoolers whose 
mothers belonged to the study groups. Due to the low prevalence of antidepressant use 
during pregnancy, the issues of small cell sizes precluded the control for potential 
confounding variables. This needs to be recognized beforehand, as it might have 
impacted the findings. Nonetheless, this study had findings consistent with the current 
literature concerning the use of antidepressants during pregnancy.  
 
5.1 Discussion Pertaining to Objective 1: Study Group Baseline Characteristics 
In regards to Objective 1, our findings from the descriptive analysis suggested 
women in the Antidepressant group were more likely to have BMI greater than or equal 
to 25 (overweight and obese) before pregnancy, were of higher parity, and more likely to 
be asthmatic compared to women in the Depressive Symptoms and Reference group.  
These findings support those of prior large Canadian population-based studies that 
investigated the relationship between antidepressant use, depression, and obesity [137-
139]. Specifically in a 10-year longitudinal cohort study, Patten et al. [137] found an 
association between obesity (BMI ≥30) and antidepressant use, particularly SSRIs and 
Venlafaxine (SNRI), but not major depressive episodes after adjusting for covariates. 
Their follow up study found that major depressive episodes and antidepressant use were 
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both associated with significant but modest increase in BMI over time [138]. In contrast, 
another Canadian cross sectional study reported a lack of association between depression 
and overweight/obesity status however an elevated risk of obesity (BMI ≥ 30) was 
observed among depressed women taking antidepressants, specifically TCAs [139].  
Generally, there is a large body of literature supporting the association between 
depression and obesity [140, 141]. Various comorbid conditions of depression, especially 
atypical depression and obesity, have been suggested to operate bi-directionally through 
interlinked psychological, behavioural, and biological (HPA-axis disruption) factors and 
share common pathological pathways involving the inflammatory, metabolic, and 
endocrine systems [140, 141]. Grundy et al. [139] suggest that, for those on 
antidepressants, antidepressant use might have played a role as an intermediate between 
the depression and obesity.  
A plausible explanation for the observed association is the side effect of weight 
gain related with antidepressant treatment. Evidence from the current literature and a 
meta-analysis indicate that the antidepressants, amitriptyline (TCA) and paroxetine 
(SSRI) are most consistently associated with clinically significant weight gain that could 
lead to overweightness or obesity [97, 100, 142, 143]. Citalopram (SSRI) has been 
reported on a fairly consistent basis to increase the risk of moderate weight gain over 
long term use [100]. Other types of SSRIs (Fluvoxamine, Sertraline, and Fluoxetine) and 
classes of antidepressants including bupropion (NDRI), venlafaxine (SNRI), and 
nefazodone (SARI) used by the women in the Antidepressant group have generally been 
found to be weight neutral and even weight loss promoting [100]. However, long term 
use of the “weight neutral” SSRIs have been reported to be associated with slight weight 
gain as well [143]. 
The proposed mechanisms underlying antidepressant induced weight gain are the 
alternation of a highly complex and overlapping network of signaling molecules 
including hormones (cortisol via HPA-axis), cytokines (leptin, tumor necrosis factor, etc), 
and neurotransmitters (serotonin, norepinephrine, etc) involved in hunger, satiety, insulin 
resistance, and overall metabolic homeostasis [97]. This manifests in an increase of 
caloric intake due to food craving, reduction resting metabolic rate, and ultimately, the 
promotion of the metabolic syndrome including obesity [97, 100]. Therefore the evidence 
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provides a strong indication that the use of antidepressants in our population may have 
played a role in the increased rate of high BMI (≥25) observed in the Antidepressant 
group and SSRI subgroup.  
During the postnatal (follow-up) survey, 87.5% and 94.1% of women in the 
Antidepressant group and SSRI subgroup, respectively reported past diagnosis of 
depression or mood disorder. Hence the underlying psychiatric illness may have been a 
contributing risk factor for high BMI (overweightness and obesity) in the Antidepressant 
group and SSRI subgroup. Confounding by prescriber expectancy might also partially 
explain this result such that physicians prescribed SSRIs to women more susceptible to 
weight gain [137].  
Overall, given evidence provided in the literature and our results, we hypothesize 
that the combined factors of antidepressant use and underlying psychiatric illness could 
have affected the risk of overweight and obesity in our sample population and those 
variables are all involved in a mutual causal pathway. However, it is worth mentioning 
that we did not model the determinants of overweight and obesity in our data because it is 
beyond the scope of this thesis.  
Moreover, the association between overweightness/obesity and asthma might 
explain the increased cases of asthma observed in women taking antidepressants. The 
increased secretion of cytokine, specifically leptin from fat tissue commonly observed in 
obesity is suggested to contribute in the pathology of asthma, a chronic inflammatory 
disorder of the airways [144]. 
Women in the Antidepressant group and Reference group were similar in regards 
to a number of characteristics including older age, married status, higher income and 
education. This is partially consistent with the literature that report pregnant women on 
antidepressants are more likely to be older [50, 145], have higher education (>12 years of 
education) [145], be recipients of welfare [50], and more likely to consume alcohol and 
smoke [145]. These high-risk behaviours during pregnancy were observed in women of 
the Depressive Symptoms group, which could be related to their demographics of lower 
education level, lower income, younger age, non-married status, and poorer mental health 
compared to other groups. All those characteristics relating to disadvantages are 
associated with higher risk of adverse lifestyle practices (concurrent alcohol and tobacco 
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use) during pregnancy [146] and are common risk factors of antenatal depression [29]. 
Furthermore, women in the Antidepressant group exhibited lower mean state anxiety 
STAI raw score than women in the Depressive Symptoms group. This result was 
expected given that depression and anxiety are frequent co-morbid conditions with 
overlapping symptoms and antidepressants have an anti-anxiety effect, which reduces the 
level of anxiety symptoms and elevates mood [146].  
The findings that women with elevated depressive symptoms during pregnancy 
were more likely to display harmful behaviours, have poorer mental health, and be 
disadvantaged are consistent with the current literature [22, 23]. This result suggests that 
women with these risk factors need to be readily recognized and require special attention 
in primary obstetric care settings in order to target screening and treatment efforts. 
However, many pregnant women with depressive symptoms are undertreated or not 
treated during this vulnerable time [18, 23], which could be the case for the women in the 
Depressive Symptoms group. Importantly, untreated depression during pregnancy can 
persist into postpartum period [147].  
 
5.2 Discussion Pertaining to Objective 2: Neonatal Outcomes 
 In regards to Objective 2, our univariable results indicated that infants exposed to 
in utero antidepressants (Antidepressant group) were at significantly higher risk to be 
LGA compared to the infants whose mothers belonged to the Depressive Symptoms and 
Reference groups. Exposure to SSRIs in utero was also found to increase the risk of LGA 
compared the Depressive Symptoms and Reference group. A previous observational 
study reported an increased risk of LGA in women exposed to antidepressants during 
pregnancy compared to the total population after adjusting for potential confounders 
(year of birth, maternal age, parity, and smoking during pregnancy), although the 
difference was not statistically significant [78]. The same result was found in their 
follow-up study [85].  
 Given the small sample size of the Antidepressant group, an analysis at the 
multivariable level was precluded, thus potential confounders were not accounted for. 
Instead, the Reference group was analyzed to investigate the maternal characteristics in 
relation to LGA. Our results from the multivariable logistic regression of the Reference 
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group found that women who were primiparous/multiparous, overweight and obese 
before pregnancy, diabetic before and/or during pregnancy, or had weight gain of 40lbs 
or more were associated with an increased odds of having LGA infants, whereas smoking 
during pregnancy was associated with decreased likelihood of having LGA infants. This 
is consistent with previous literature [96, 148] and other analyses in this dataset citing 
these maternal factors as strong predictors of delivering LGA infants [149]. Thus it is 
possible that these maternal characteristics known to affect insulin resistance may offer 
an explanation for the increased frequency of LGA in the Antidepressant group. 
 Although antidepressant use is not a known risk factor for delivering LGA 
infants, observational studies have produced sufficient data indicating the association 
between antidepressant use, particularly TCAs and SSRIs, and the risk factors pertaining 
to LGA including insulin resistance [98], dyslipidemia [98, 150], diabetes [99, 151], and 
as discussed above (Section 5.1), obesity [100]. Specifically, in a Norwegian general 
community cross sectional study, overall SSRI use was found to be associated with 
abdominal and general obesity, hypercholesterolemia, and an observed trend toward 
diabetes [98]. A meta-analysis of 12 high quality observational studies concluded that 
there was a significantly increased risk of type 2 diabetes mellitus among long-term users 
of SSRIs and TCAs after adjusting for body weight, depression severity, and physical 
activity [152]. Additionally, consistent data from the literature review suggested the use 
of paroxetine increases the risk of dyslipidemia and glucose intolerance [100]. The 
increased risk of diabetes among women in the Antidepressant group and SSRI subgroup 
was not observed. As a result, it is assumed that their glucose tolerance, albeit not 
considered in our study, might have been compromised to a certain degree given Grave et 
al. [149] found abnormal glucose tolerance as a significant risk factor of LGA in this 
dataset.  
 Generally, it is suspected that antidepressants increase serum cortisol level and 
insulin resistance by altering the HPA axis [153]. Specifically, TCAs inhibit 
noradrenaline reuptake transporters at the synapses increasing noradrenaline, which then 
leads to a hyperglycemic effect [99]. Furthermore, some SSRIs have been found to 
activate insulin receptor 1 kinases resulting in inhibition of insulin signaling and 
induction of cellular insulin resistance [154]. Therefore we hypothesized that the 
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antidepressant-induced hyperglycemic effect during pregnancy increases glucose 
availability and delivery to the fetus resulting in fetal hyperinsulinemia and increases the 
risk of LGA. Dyslipidemia in pregnant women has also been found to have a positive 
influence on fetal growth due to increased serum lipid availability [155]. In addition, the 
relationship between the risk of LGA and pre-pregnancy BMI is directly proportional and 
independent of gestational diabetes in women with adequate gestational weight gain [96]. 
So in connection to Discussion section 5.1, the increased rate of high BMI (≥25) in the 
Antidepressant group may be a main factor explaining the increased frequency of LGA 
infants in this group. Overall, the mechanism of antidepressants induces unwanted side 
effects that fit under the umbrella of metabolic syndrome and could have potentially 
contributed to LGA in the Antidepressant group.  
On the other hand, because antidepressant use occurs in the context of underlying 
depression, the comorbid conditions of depression and obesity are worthy of discussion 
since they share common pathological pathways such as increased level of pro-
inflammatory cytokines, insulin resistance, and altered plasma glucose levels [156], 
which could contribute to LGA as well.  
 Furthermore, infants exposed to antenatal SSRIs had an increased risk of being 
preterm compared to infants of the Reference group. Results regarding the relationship 
between antenatal SSRI exposure and premature birth have been inconsistent in the 
literature [21, 79]. Evidence indicates that longer duration [76] and late trimester (2nd and 
3rd) [157, 158] exposure of antenatal SSRIs is associated with preterm birth and other 
adverse birth outcomes. We had limited information on the timing and duration of 
antidepressant use in our database. Research has demonstrated that antidepressant use 
decreases significantly once pregnancy is identified from the rate of 6.6% (12 months 
before gestation) to 3.7% (first trimester) and continues to decrease to 1.6% (second 
trimester) and 1.1% (third trimester) [50]. Most women in the Antidepressant group and 
SSRI subgroup were in the second trimester (38 out of 44 and 29 out of 32) and the rest 
in the first trimester at the time of the prenatal survey. Coupled with the fact that most 
pregnant women take antidepressant for a prolonged period as maintenance therapy to 
prevent recurrences of psychiatrics episodes [145], it is likely that majority of women 
were adherent to the treatment throughout pregnancy and the difference in the timing and 
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duration of exposure did not greatly affect our results. Furthermore, it is possible that the 
increased risk of preterm birth observed in the SSRI subgroup may be confounded by the 
underlying maternal depression.  
 Additionally, non-significant increases in the risk of low Apgar-1, Apgar-5, and 
TSC were observed in infants exposed to in utero antidepressants. However, due to both 
the exclusion of preterm infants and the sample size limitation, these adverse outcomes 
were rare events with low frequency count for the Antidepressant group and SSRI 
subgroup. Therefore we had low statistical power to detect significant differences.  
 
5.3 Discussion Pertaining to Objective 3: Toddler/Child Development 
In regards to Objective 3, our descriptive analysis found lower mean scores in the 
communication, fine and gross motor movement, and personal/social skill domains of the 
ASQ among toddlers and children whose mothers that belonged in the SSRI subgroup 
during pregnancy in comparison to the other groups. The largest deficit was observed in 
the fine and gross motor domains by a maximum difference margin of approximately 7 
points between the SSRI subgroup versus both the Depressive Symptoms and Reference 
group. Furthermore, consistent with all previous studies that investigated cognitive 
development [9, 12, 101-104, 121], we did not observe a deficit in the mean score for the 
problem-solving domain among toddlers and children in the SSRI subgroup. The 
interpretation of our results warrants caution since the sample size was small and we were 
unable to control for confounders. As a result, the clinical significance is not known.  
Nonetheless, our preliminary findings are supported by several observational 
studies that found a deficit in motor development among children exposed to antenatal 
SSRIs. Specifically, a few small sized studies (31 to 51 exposed participants) reported an 
association between SSRI use during pregnancy and significantly lower scores on the 
Bayley Psychomotor Developmental Index particularly in the gross motor development 
in two studies [104, 109] and in the fine motor and tremulousness sub-scores of the 
Bayley Behavioural Rating Scales in another study [103]. However, Casper et al. [104] 
reported normal range of motor development after the neurological exam. Additionally, a 
large cohort-based Danish population study [12] found that 6 month old children who 
were exposed to SSRIs during second and third trimester had increased odds of delayed 
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gross motor development, specifically sitting without support compared to children of 
untreated mothers even after adjusting for covariates including postnatal symptoms of 
depression. Again, the motor development milestones were within the normal expected 
range and the gross motor delays were resolved at the age of 19 months. Other studies 
have also reported a transient motor delay in the infancy and early toddlerhood (1-1.5 
years) stages that later resolves past approximately 1.5 years of age [11, 121]. The 
authors of these studies suggested in utero SSRI exposure may impact early fetal motor 
development that is self-limiting later in infancy and young toddlerhood due possibly to a 
washout effect, however our study and other studies [103, 104] indicate that motor 
impairment might persist to the ages of two to five years. Therefore further follow-up 
studies are needed to clarify the persistence of fetal SSRI exposure on motor 
development in children. This finding was not completely unanticipated since the role of 
serotonin is essential in the maturation of the sensorimotor areas during development, 
including the cerebellum, basal ganglia and those areas innervated by and under the 
control of serotonergic fibers [159].  
We observed a difference margin of approximately 3 points in the communication 
and personal/social domains between the SSRI subgroup versus both the Depressive 
Symptoms and Reference group. Again, whether this 3-point difference is statistically or 
clinically significant is inconclusive, however these potential developmental deficits are 
supported by previous observational and animal model studies. A recent large Norwegian 
population-based cohort study reported that prolonged in utero SSRI exposure was 
associated with moderate language delays in 3 year olds independent of the underlying 
maternal depression before, during, and after pregnancy [111]. However the authors 
suggested moderate language delay may later resolve since severe language delay or 
clinical delay was not included as part of the outcome. No other studies to date have 
found an association between communication or language delay and antenatal SSRI 
exposure [101, 102, 109, 115]. Therefore even if our result was statistically significant, 
the clinical importance for communication deficit is unlikely based on evidence from the 
literature. 
In addition, the majority of studies suggested that antenatal SSRI exposure was 
not associated with an increased risk of personal/social behavioural problems in children 
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[9, 10, 13, 101, 102, 106, 107], although, a few observational [12, 104, 108, 110] and 
animal studies [160, 161] did find such an association. For example, previous 
observational research has illustrated that antenatal exposure to SSRIs was associated 
with increased risk of lower Behavior Rating Score (orientation/engagement, emotional 
regulation, and motor quality) in a small sample of 12 to 40 month olds [104], inability to 
occupy themselves alone for 15 minutes (attention) in 19 month olds after controlling for 
postnatal depressive symptoms [12], and higher levels of internalizing behaviour 
(withdrawal, anxiety, depression) in 3 and 6 year olds after controlling maternal mood 
during antenatal, postnatal, and childhood period [110]. In animal models, the early 
administration of SSRIs in neonates and the subsequent increase in serotonin level have 
been shown to cause permanent impairment in the neural connection of the 
somatosensory cortex, as well as impairment in social behaviours such as reduced 
exploratory behaviour and depressive and anxiety-related behaviour in adulthood [160, 
161]. Recently, in utero SSRI exposure was found to be associated with a change in 
serum concentration of proteins such as reelin and activin A that are imperative in early 
neurodevelopment during gestation in humans [124, 125].  
Since our analysis was descriptive, there remains a significant possibility for 
confounding variables such as the severity of underlying antenatal and postnatal maternal 
psychiatric illnesses and its related behaviours to affect our findings in the long-term 
development of children. For instance, Nulman et al. [9] reported that children exposed to 
SSRIs had a lower IQ compared to children not exposed to SSRIs. However, regression 
analysis discovered that the severity of maternal depression during and after pregnancy 
and maternal IQ predicted problematic behaviour and cognitive outcomes, respectively, 
while duration and dose of antidepressant exposure during pregnancy did not predict 
developmental outcomes. Similarly, Misri et al. [107] discovered that current maternal 
depression and anxiety were associated with increased internalizing behaviour and not 
SSRI use. On the other hand, Oberlander et al. [105] found that antenatal exposure to 
SSRIs in combination with current maternal anxiety were associated with an increased 
rate of internalizing behavior at 3 years of age. This suggests that there may be a complex 
association between underlying maternal mental disorders, medication use, and the long-
term developmental outcome.  
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At this point, the significance of our results on long-term development remains 
uncertain and whether these “deficits” manifest in clinically relevant issues later in life is 
even more unclear and doubtful. Based on the literature, this area of research is still in the 
beginning stages without a definitive conclusion regarding the clinical relevance due to 
the challenges in designing observational studies with adequate sample size that accounts 
for residual confounding variables. However, the use of SSRIs during pregnancy could 
increase the risk of some development delays involving psychomotor and personal/social 
behavioural development with unknown clinical implications. The future direction for 
this research area is discussed in section 5.5.  
 
5.4 Strengths and Limitations  
One of the main strengths of this study was the inclusion of women with 
depressive symptoms but not taking antidepressants, which to some degree allowed us to 
directly examine the effect of antidepressant exposure on neonatal and long-term 
outcomes independent from potential underlying maternal illness and account for any 
unmeasured or unidentified variables associated with having depressive symptoms. In 
addition, women who participated in the PHP were unaware of the aim of this study when 
filling out the ASQ, therefore participant bias was unlikely present. Another strength of 
this study was the benefit of utilizing the well-designed PHP dataset, which prospectively 
collected a plethora of information on relevant pregnancy exposures and neonatal and 
child development outcomes. For instance, although clinical diagnosis of psychiatric 
illnesses and its severity were unknown, the PHP utilized widely validated psychological 
screening tests including the CES-D and STAI to identify individuals at risk for clinical 
depression and to detect the incidence and severity of state anxiety symptoms, 
respectively [162, 163].  Additionally, the CES-D is widely used in antenatal research and 
recommended as an initial assessment for depressive symptoms during pregnancy [25]. 
Furthermore, we were able to use the Canadian population reference to account for 
gestational age when examining birth weight where many previous studies had not done 
so [21]. From the postnatal survey, 87.5% and 94.1% of women in the Antidepressant 
group and SSRI subgroup, respectively reported past diagnosis of depression or mood 
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disorder so it is likely that the indication of antidepressant use was for what it was 
intended.   
Given the PHP was not designed to investigate this specific thesis topic, we 
acknowledge a number of limitations. As previously mentioned, we were unable to 
produce precise risk estimates and control for confounding variables because of the small 
number of women taking antidepressant in our study sample. This relatively low 
prevalence of antidepressant use is comparable to many observational studies being one 
of the common challenges in this research area. To compensate for the lack of robust 
statistical analysis, this thesis provided a concise descriptive analysis and thorough 
literature review on the neonatal and long-term outcomes of antidepressant use during 
pregnancy. Furthermore, our method of controlling for confounding by indication for the 
treatment may have introduced selection bias since women who opt for treatment during 
pregnancy may be inherently different from women who do not receive treatment during 
pregnancy. For instance, it is probable that women with more severe psychiatric illness 
were required to continue their treatment during pregnancy, which may have 
overestimated the impact of antidepressant use on neonatal and long-term developmental 
outcomes. Ramos et al. [50] support this notion by reporting that pregnant women who 
initiate or continue antidepressant treatment were more likely to have a higher number of 
prescribers, a higher number of visits to the doctors before pregnancy, and a depression 
diagnosis before or during pregnancy. 
The potential for misclassification of variables due to self-reporting and recall 
bias needs to be recognized. Specifically, self-reported height and weight used for the 
calculation of pre-pregnancy BMI might be underestimated from the overestimation of 
height and underestimation of weight. Misclassification of weight gained during 
pregnancy also needs to be addressed because it was captured as a categorical variable 
without accounting for the recommended weight gain based on the maternal BMI. For 
instance, the recommended range of total weight gain during pregnancy for an 
overweight woman is 15-25lbs and using our categorization would misclassify their 
weight gain as appropriate (21lbs-39lbs) [149]. Antidepressant medication use was also 
self-reported by participants, however they were asked to list all the medication used 
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currently at the time of the survey as well as the amount and frequency of use thereby 
reducing the likelihood of recall bias.  
The ASQ is a validated developmental screening tool compared to other 
professionally administered assessments such as the Bayley Scale of Infant Development 
[164]. However, the reliance on the ASQ to assess child developmental is another 
limitation worth mentioning since we did not utilize the ASQ as it was intended as a 
dichotomized outcome (pass or fail) test. Nonetheless, the intention was not to investigate 
the individual pass or fail but to utilize the continuous ASQ scores for its ability to 
compare scores among different groups. The ASQ may also underestimate developmental 
delays and generally identify development as normal given the evidence of the negative 
skew distribution and ceiling effect in our sample population. The benefit, however, of 
utilizing the ASQ is that it can be self-administered quickly and easily at home by parents 
[164].  
In addition, self-reported evaluation of child development using the ASQ might 
have been influenced by maternal mood because psychologically distressed mothers have 
the propensity to over-report or underreport their child development resulting in 
inaccurate assessment [165, 166]. Furthermore, developmental assessment was reported 
at a single time point, which might have restricted our result, as child development is 
likely to change over time. On a related note, whether depressive symptoms persists 
throughout pregnancy or discontinues is unknown given CES-D was utilized at a single 
time frame. However, depressive symptoms have been found to persist and remain 
uniform through pregnancy [167]. Lastly, this is an observational study, therefore the 
direction of effect or causality between exposure and outcome cannot be confirmed.  
 
5.5 Conclusion and Future Directions 
The main goal of this thesis was to differentiate the effect of antenatal 
antidepressant exposure from that of antenatal maternal depressive symptoms on neonatal 
health and subsequent long-term development. By doing so, our univariable results 
suggests that newborns exposed to antidepressants and SSRIs in utero had an increased 
risk of being LGA compared to infants born to untreated women with depressive 
symptoms and healthy women. However, this could be explained by third-variable 
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factors including high pre-pregnancy BMI possibly induced by the combination of 
antidepressant use and underlying depression. Additionally, newborns exposed to SSRIs 
in utero had an increased risk of being preterm compared to infants born to healthy 
women. We also observed lower mean ASQ scores in the fine motor, gross motor, 
communication, and personal/social domains among children exposed to in utero SSRIs 
in our descriptive analysis. Our findings contribute to the growing literature on antenatal 
antidepressant use and its potential risks, yet it is important to acknowledge that these 
findings are still tentative and further studies with larger sample size are needed.  
In this area of research, it is challenging to design observational 
pharmacoepidemiological studies without encountering some level of confounding by 
indication, residual confounding, and small sample size of exposure group. In addition, 
the heterogeneity of study design across the literature makes it extremely difficult to 
formulate any conclusions on the risk or benefits of antidepressant use during pregnancy 
for clinical recommendations. For instance, currently there is not a single meta-analysis 
on antidepressant exposure during pregnancy and its effect on child development due to 
the diverse methodologies and outcome measures in the literature.  
Thus, in order for advancement in this field of research, new strategies are 
needed, especially for the investigation of long-term developmental outcomes. Recently, 
sibling discordance designs have been implemented that allowed for the control of 
familial and genetic factors, however this design is limited by sample size and potential 
bias by other discordance factors [168]. Another approach is to include participants 
receiving different antidepressant medication for the same underling disease, however 
cross interaction of neurotransmitters limits this method. Perhaps, then, well-designed 
randomized controlled trials (RCTs) are the future direction for this area of research as 
recommended by El Marroun et al. [145], since RCTs are immune from confounding by 
indication. They advise recruiting women who are planning for pregnancy and 
considering the cessation of their maintenance pharmacotherapy in order to address the 
ethical dilemma. Moreover, future studies, albeit extremely difficult, need to include the 
importance and complexity of genetic polymorphism of cytochrome P450 enzymes 
(CYPs) as different CYPs metabolize certain antidepressants more effectively which 
could provide an explanation for the difference in study outcomes [169].  
77 
 
 
 Overall the results from this thesis do not warrant any changes in the current 
clinical practices nor diminish the importance of antidepressant treatment in cases of 
recurrent and severe depression; however, our results will bring awareness of the possible 
risks of antidepressant use and contribute to the developing literature. There are indeed 
complex challenges in treating depression and other psychiatric illness during pregnancy 
due to the potential unwanted drug effects and unwanted effect of untreated depression 
on the offspring. Ultimately, it is crucial for clinicians to thoroughly discuss the risk and 
benefits of the specific antidepressant treatment during pregnancy to patients on a case-
by-case basis for patients to make well-informed decisions for the well-being of both the 
mothers and their children.  
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Appendices 
Appendix A: Animal model literature review  
 
In rodent studies, the phenomenon of paradoxical behaviour outcomes has been 
noted, meaning that SSRIs administered during early neurodevelopmental period 
(antenatal, neonatal, and adolescent) causes anxiety- and depression-like behaviours in 
adulthood, whereas SSRI exposure during adulthood has the opposite behavioural effects 
[1]. This observed paradox is likely explained by SSRI-induced changes in neural 
serotonin levels during critical neurodevelopment periods [2].  
A study conducted by Hansen et al. [3] was the first to find an adverse long-term 
neurobehavioural effect of SSRI exposure. SSRIs were administered during 8th to 21st 
postnatal days, which corresponded to the events of brain maturation that began during 
the third trimester of pregnancy and early childhood in humans. At the age of fourth 
months, both saline- and SSRI-treated groups were assessed in open field, forced swim, 
and social interaction tests. A significant difference was only found in the forced swim 
test where the SSRI-treated group had a prolonged immobility time, which was purported 
to represent behavioural despair and negative mood. This result indicates that the central 
serotonergic system play a role in the pathology of depression.   
An innovative study performed by Ansorge et al. [4] administered fluoxetine or 
saline postnatally from day 4 to 21 for mice of different serotonin transport (5-HTT) 
genotypes. Tests were conducted 9 weeks after the last injection of fluoxetine or saline. 
Decreased exploratory behaviours, longer latencies to begin feeding, and longer average 
latency to escape foot shock were observed in wildtype (5-HTT+/+) and heterozygous (5-
HTT+/-) mice treated with fluoxetine compared to those treated with saline. Similar 
behaviours were detected in mutated (5-HTT-/-) mice that were treated with either 
fluoxetine or saline. These results suggest that alteration of neural serotonin level either 
by permanent genetic modification of 5-HTT or transient SSRI treatments during critical 
neurodevelopment periods changes the neural connections in the central nervous system 
(CNS) that regulate depression- and anxiety-related behaviours in adulthood. 
Increased neural serotonin concentration during the neurodevelopmental stages 
may also affect aggression in adulthood. Manhães de Castro et al. [5] investigated the 
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degree of aggression in adult mice (90-120 days old) exposed to citalopram from 1st to 
19th postnatal days. The duration of aggressive behaviour in the mice treated with 
citalopram decreased by 41.4% compared to the control group. Additionally, Maciag et 
al. [6] found decreased expression of tryptophan hydroxylase (rate-limiting serotonin 
synthetic enzyme) and 5-HTT in the CNS of adult mice exposed to citalopram postnatally 
(8-21 days). Motor movement activity and sexual behavior were increased and decreased, 
respectively [6]. Another study found anatomical changes in the fine neural wiring of the 
somatosensory cortex in adult rats exposed to fluoxetine postnatally (0-6 days) [7]. 
Consequently, behavioural deficits related to somatosensory, such as tactile impairment, 
thermal perceptions delay, and locomotion activity reduction (exploratory behavioural 
reduction), were observed [7].  
Popa et al. [8] also discovered depression-like behaviours such as an increase in 
rapid eye movement (REM) sleep and anhedonia in mice exposed to escitalopram during 
early postnatal life. The depressive symptoms, however, improved after long-term 
escitalopram treatment. Similar to the findings of Ansorge et al. [4], mice with 
genetically deficient expression of 5-HTT had comparable depression-like symptoms as 
the mice that were treated transiently with escitalopram during postpartum periods.  
Bairy et al. [9] also reported transient motor development delay in rats exposed to 
antenatal fluoxetine (6th to 20th day of pregnancy), but other behavioural outcomes were 
not negatively affected. Interestingly, rats exposed to higher doses of fluoxetine 
performed well in the water maze test, which suggested an improvement in cognitive 
abilities, particularly in learning and memory. In a similar study, pups exposed to 
antenatal SSRIs had anxiety-like behaviours accompanied with decrease in social 
behaviours during adulthood, but behavioural despair, anhedonia, and abnormal sexual 
behaviour were not detected [10]. Lastly, mice pups exposed to fluoxetine during 
pregnancy and lactation had decreased ambulation, impulsivity (as demonstrated via the 
intruder-resident test), and increased immobility time (forced swim test) [11].  
In conclusion, the above-mentioned studies were suggestive of adverse 
behavioural changes, specifically depression- and anxiety-like symptoms, which 
developed in adult rodents exposed to SSRIs during crucial neurodevelopment phases.  
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Appendix B: Conceptual model  
 
Figure B1: Conceptual model based on literature review: neonatal and developmental outcomes of antenatal depressive 
symptoms and antidepressant exposure  
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Appendix C: Relevant Sections from the Prenatal Health Project Questionnaire.  
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